uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q34.1605 | Q34 | What are the names of the genes that are targeted by the drug Enalapril Maleate in the treatment of hypertension? | In the context of hypertension, the drug Enalapril Maleate targets the gene angiotensin I converting enzyme. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%enalapril maleate%" OR LOWER(tradeNames_list) LIKE "%enalapril maleate%" OR LOWER(syns_list) LIKE "%enalapril maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1091900', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091924', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091932', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091940', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091956', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091964', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091972', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091988', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091996', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092004', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092012', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092028', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092036', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092044', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092052', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092060', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092068', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092076', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092084', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091980', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091916', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091884', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091868', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091860', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1092020', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091948', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091908', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091892', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}, {'UUID': 'DrugTargetsIndication121923_text_1091876', 'drugName': 'Enalapril Maleate', 'tradeNames_list': "['Ednyt', 'Enalapril maleate', 'Enapren', 'Epaned', 'Epaned kit', 'InnovacePralenal 10', 'Pralenal 2.5', 'Pralenal 20', 'Pralenal 5', 'RenitecVasotec', 'Xanef']", 'syns_list': "['Enalapril maleate', 'MK-421', 'NSC-758143']", 'yearOfFirstApproval': 1985, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.532 | Q34 | What are the names of the genes that are targeted by the drug Carbinoxamine Maleate in the treatment of angioedema? | In the context of angioedema, the drug Carbinoxamine Maleate targets the gene histamine receptor H1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%angioedema%" OR LOWER(efo_term) LIKE "%angioedema%") AND (LOWER(drugName) LIKE "%carbinoxamine maleate%" OR LOWER(tradeNames_list) LIKE "%carbinoxamine maleate%" OR LOWER(syns_list) LIKE "%carbinoxamine maleate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455850', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}, {'UUID': 'DrugTargetsIndication121923_text_455856', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_list': "['Carbinoxamine maleate', 'Clistin', 'Davenol', 'Karbinal er']", 'syns_list': "['Carbinoxamine maleate', 'NSC-62362']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema', 'approvedSymbol': 'HRH1', 'approvedName': 'histamine receptor H1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.348 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of osteoarthritis? | In the context of osteoarthritis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoarthritis%" OR LOWER(efo_term) LIKE "%osteoarthritis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_230369', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228659', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230939', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228374', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226379', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229514', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231224', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231509', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228944', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227234', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229229', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227519', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227804', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231794', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230084', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232079', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230654', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228089', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229799', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232364', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226664', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226949', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226396', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227821', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229531', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229246', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230386', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229816', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226966', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230101', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226111', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227251', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228391', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230671', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230956', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228676', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231241', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231526', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226681', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227536', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228961', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231811', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232096', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228106', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1372 | Q34 | What are the names of the genes that are targeted by the drug Abaloparatide in the treatment of osteoporosis? | In the context of osteoporosis, the drug Abaloparatide targets the gene parathyroid hormone 1 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%osteoporosis%" OR LOWER(efo_term) LIKE "%osteoporosis%") AND (LOWER(drugName) LIKE "%abaloparatide%" OR LOWER(tradeNames_list) LIKE "%abaloparatide%" OR LOWER(syns_list) LIKE "%abaloparatide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1025249', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025246', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025252', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025255', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025258', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Osteoporosis', 'efo_term': 'osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025248', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025245', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025251', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025257', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1025254', 'drugName': 'Abaloparatide', 'tradeNames_list': "['Tymlos']", 'syns_list': "['Abaloparatide', 'BA-058', 'BA058', 'BIM-44058']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoporosis, Postmenopausal', 'efo_term': 'postmenopausal osteoporosis', 'approvedSymbol': 'PTH1R', 'approvedName': 'parathyroid hormone 1 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1941 | Q34 | What are the names of the genes that are targeted by the drug Migalastat Hydrochloride in the treatment of Fabry disease? | In the context of Fabry disease, the drug Migalastat Hydrochloride targets the gene galactosidase alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%fabry disease%" OR LOWER(efo_term) LIKE "%fabry disease%") AND (LOWER(drugName) LIKE "%migalastat hydrochloride%" OR LOWER(tradeNames_list) LIKE "%migalastat hydrochloride%" OR LOWER(syns_list) LIKE "%migalastat hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192175', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192178', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192179', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192180', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192182', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192183', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192184', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192186', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192187', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192188', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192189', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192191', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192192', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192193', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192194', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192195', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192196', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192197', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192198', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192199', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192200', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192202', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192203', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192204', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192205', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192206', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192208', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192209', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192210', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192211', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192212', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192213', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192214', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192215', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192201', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192185', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192177', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192173', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192171', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192170', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192207', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192190', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192181', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192176', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192174', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192172', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_list': "['Galafold']", 'syns_list': "['AT-1001 (MIGALASTAT HYDROCHLORIDE)', 'Migalastat hclMigalastat hydrochloride']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fabry Disease', 'efo_term': 'Fabry disease', 'approvedSymbol': 'GLA', 'approvedName': 'galactosidase alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1829 | Q34 | What are the names of the genes that are targeted by the drug Cyclosporine in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Cyclosporine targets the gene peptidylprolyl isomerase A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%cyclosporine%" OR LOWER(tradeNames_list) LIKE "%cyclosporine%" OR LOWER(syns_list) LIKE "%cyclosporine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1101282', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101663', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101790', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101917', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102171', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102298', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102425', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102679', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102806', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102933', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1103060', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101536', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101028', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100774', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100647', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102552', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102044', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101409', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101155', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100901', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1953 | Q34 | What are the names of the genes that are targeted by the drug Baclofen in the treatment of spinal cord disease? | In the context of spinal cord disease, the drug Baclofen targets the gene gamma-aminobutyric acid type B receptor subunit 1 and gamma-aminobutyric acid type B receptor subunit 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%spinal cord disease%" OR LOWER(efo_term) LIKE "%spinal cord disease%") AND (LOWER(drugName) LIKE "%baclofen%" OR LOWER(tradeNames_list) LIKE "%baclofen%" OR LOWER(syns_list) LIKE "%baclofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193245', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193320', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193345', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193295', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193145', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193120', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193195', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193270', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR2', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_1193220', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_1193170', 'drugName': 'Baclofen', 'tradeNames_list': "['Baclofen', 'Baclospas-10', 'Fleqsuvy', 'Gablofen', 'Kemstro', 'LioresalLioresal intrath', 'Lyflex', 'Lyvispah', 'Ozobax']", 'syns_list': "['(rs)-baclofen', 'BA-34,647', 'BA-34647', 'Baclofen', 'Fleqsuvy', 'LyvispahNSC-755906']", 'yearOfFirstApproval': 1977, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Spinal Cord Diseases', 'efo_term': 'spinal cord disease', 'approvedSymbol': 'GABBR1', 'approvedName': 'gamma-aminobutyric acid type B receptor subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.975 | Q34 | What are the names of the genes that are targeted by the drug Fostamatinib Disodium in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Fostamatinib Disodium targets the gene spleen associated tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%fostamatinib disodium%" OR LOWER(tradeNames_list) LIKE "%fostamatinib disodium%" OR LOWER(syns_list) LIKE "%fostamatinib disodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_848772', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848793', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848800', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848807', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848821', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848828', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848835', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848849', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848856', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848863', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848870', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848884', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848891', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848898', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848905', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848912', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848919', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848926', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848842', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848786', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848758', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848744', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848737', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848877', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848814', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848779', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848765', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_848751', 'drugName': 'Fostamatinib Disodium', 'tradeNames_list': "['Tavalisse']", 'syns_list': "['Fostamatinib disodium', 'Fostamatinib disodium hexahydrateFostamatinib disodium salt hexahydrate', 'Fostamatinib sodium hydrateR-788 SODIUM', 'R-788 SODIUM HYDRATE', 'R-935788 SODIUMR-935788 SODIUM HYDRATE', 'R788 SODIUM', 'R788 SODIUM HYDRATER935788 SODIUM', 'R935788 SODIUM HYDRATE']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'SYK', 'approvedName': 'spleen associated tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.606 | Q34 | What are the names of the genes that are targeted by the drug Ranolazine in the treatment of cardiovascular disease? | In the context of cardiovascular disease, the drug Ranolazine targets the gene sodium voltage-gated channel alpha subunit 5 and sodium voltage-gated channel alpha subunit 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cardiovascular disease%" OR LOWER(efo_term) LIKE "%cardiovascular disease%") AND (LOWER(drugName) LIKE "%ranolazine%" OR LOWER(tradeNames_list) LIKE "%ranolazine%" OR LOWER(syns_list) LIKE "%ranolazine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_662707', 'drugName': 'Ranolazine', 'tradeNames_list': "['Aspruzyo sprinkle', 'Ranexa', 'Ranolazine']", 'syns_list': "['Aspruzyo', 'CVT-303', 'NSC-759100', 'RS-43285-003', 'Ran d', 'Ranolazine']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_662724', 'drugName': 'Ranolazine', 'tradeNames_list': "['Aspruzyo sprinkle', 'Ranexa', 'Ranolazine']", 'syns_list': "['Aspruzyo', 'CVT-303', 'NSC-759100', 'RS-43285-003', 'Ran d', 'Ranolazine']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiovascular Diseases', 'efo_term': 'cardiovascular disease', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1416 | Q34 | What are the names of the genes that are targeted by the drug Lumasiran Sodium in the treatment of primary hyperoxaluria type 1? | In the context of primary hyperoxaluria type 1, the drug Lumasiran Sodium targets the gene hydroxyacid oxidase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%primary hyperoxaluria type 1%" OR LOWER(efo_term) LIKE "%primary hyperoxaluria type 1%") AND (LOWER(drugName) LIKE "%lumasiran sodium%" OR LOWER(tradeNames_list) LIKE "%lumasiran sodium%" OR LOWER(syns_list) LIKE "%lumasiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1041087', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041090', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041091', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041092', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041089', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041085', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041083', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041082', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041093', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041088', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041086', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1041084', 'drugName': 'Lumasiran Sodium', 'tradeNames_list': "['Oxlumo']", 'syns_list': "['Lumasiran sodium']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hyperoxaluria, Primary', 'efo_term': 'primary hyperoxaluria type 1', 'approvedSymbol': 'HAO1', 'approvedName': 'hydroxyacid oxidase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.245 | Q34 | What are the names of the genes that are targeted by the drug Triamcinolone Acetonide in the treatment of pulmonary tuberculosis? | In the context of pulmonary tuberculosis, the drug Triamcinolone Acetonide targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary tuberculosis%" OR LOWER(efo_term) LIKE "%pulmonary tuberculosis%") AND (LOWER(drugName) LIKE "%triamcinolone acetonide%" OR LOWER(tradeNames_list) LIKE "%triamcinolone acetonide%" OR LOWER(syns_list) LIKE "%triamcinolone acetonide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_222205', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222335', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222075', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221945', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_221880', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222270', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222140', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_222010', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'syns_list': "['FX-006', 'FX006', 'Kenacourt', 'NSC-21916', 'Triamcinolone AcetonideTriamcinolone acetonide']", 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1505 | Q34 | What are the names of the genes that are targeted by the drug Pralatrexate in the treatment of neoplasm? | In the context of neoplasm, the drug Pralatrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%pralatrexate%" OR LOWER(tradeNames_list) LIKE "%pralatrexate%" OR LOWER(syns_list) LIKE "%pralatrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1072438', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072457', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072533', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072514', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072534', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072439', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072496', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072495', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072458', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072476', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072477', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072515', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072453', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072471', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072488', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072507', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072510', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072490', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072491', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072472', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072526', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072431', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072529', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072469', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072509', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072434', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Lung Neoplasms', 'efo_term': 'lung cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072528', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072452', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072433', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Head and Neck Neoplasms', 'efo_term': 'head and neck malignant neoplasia', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072450', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072428', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072447', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072466', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072504', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072506', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072467', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072468', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072505', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072525', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072448', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072523', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072524', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072429', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072449', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072430', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072485', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Peritoneal Neoplasms', 'efo_term': 'peritoneum cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072486', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Fallopian Tube Neoplasms', 'efo_term': 'fallopian tube cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1072487', 'drugName': 'Pralatrexate', 'tradeNames_list': "['Folotyn']", 'syns_list': "['NSC-754230', 'PDX', 'Pralatrexate']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1070 | Q34 | What are the names of the genes that are targeted by the drug Ticagrelor in the treatment of acute myocardial infarction? | In the context of acute myocardial infarction, the drug Ticagrelor targets the gene purinergic receptor P2Y12. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute myocardial infarction%" OR LOWER(efo_term) LIKE "%acute myocardial infarction%") AND (LOWER(drugName) LIKE "%ticagrelor%" OR LOWER(tradeNames_list) LIKE "%ticagrelor%" OR LOWER(syns_list) LIKE "%ticagrelor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_920469', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920547', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920573', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920599', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920651', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920677', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920703', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920755', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920781', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920807', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920833', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920885', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920911', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920937', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920963', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920989', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920729', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920521', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920417', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920365', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920339', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920859', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920625', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920495', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920443', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}, {'UUID': 'DrugTargetsIndication121923_text_920391', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'syns_list': "['AR-C126532XX', 'AZD-6140', 'AZD6140', 'Possia', 'Ticagrelor']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'acute myocardial infarction', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1462 | Q34 | What are the names of the genes that are targeted by the drug Tazarotene in the treatment of acne? | In the context of acne, the drug Tazarotene targets the gene retinoic acid receptor gamma, retinoic acid receptor beta and retinoic acid receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%tazarotene%" OR LOWER(tradeNames_list) LIKE "%tazarotene%" OR LOWER(syns_list) LIKE "%tazarotene%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1055500', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055524', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055532', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055540', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055516', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055484', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055468', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055460', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}, {'UUID': 'DrugTargetsIndication121923_text_1055548', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARA', 'approvedName': 'retinoic acid receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1055508', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055492', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARB', 'approvedName': 'retinoic acid receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_1055476', 'drugName': 'Tazarotene', 'tradeNames_list': "['Arazlo', 'Avage', 'Fabior', 'Tazorac', 'Zorac']", 'syns_list': "['AGN 190168', 'AGN-190168', 'Idp-123', 'Tazarotene']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'RARG', 'approvedName': 'retinoic acid receptor gamma'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.314 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of eye inflammation? | In the context of eye inflammation, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%eye inflammation%" OR LOWER(efo_term) LIKE "%eye inflammation%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227770', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228625', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228910', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229195', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229765', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230050', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230335', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230905', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231190', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231475', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231760', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232330', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230620', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228340', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227200', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226630', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226345', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232045', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229480', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228055', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227485', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226915', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Eye Diseases', 'efo_term': 'eye inflammation', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.439 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361085', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361244', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361297', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361350', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361456', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361509', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361562', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361668', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361721', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361774', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361827', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361933', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361986', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362039', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362092', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362145', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362198', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362251', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362304', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362357', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362410', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362516', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362569', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362622', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362675', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362728', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362834', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362887', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362940', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362993', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363046', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363099', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363152', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363205', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363258', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363311', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363364', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363417', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363470', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363523', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363576', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363629', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363682', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363735', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363788', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363841', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363894', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363947', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364000', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364053', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364106', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364212', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364265', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364318', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364371', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364424', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364477', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364583', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364636', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364689', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364742', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364795', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364848', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364901', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364954', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365007', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365060', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365113', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365166', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365219', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365272', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365325', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365378', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365431', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365484', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365537', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365590', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365643', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365696', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365749', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365802', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365855', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365908', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365961', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366014', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366067', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364159', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362463', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361615', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361191', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360979', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360873', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360820', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364530', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362781', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361880', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361403', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361138', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361032', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360926', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1880 | Q34 | What are the names of the genes that are targeted by the drug Cobicistat in the treatment of infection? | In the context of infection, the drug Cobicistat targets the gene cytochrome P450 family 3 subfamily A member 4, cytochrome P450 family 3 subfamily A member 5, cytochrome P450 family 3 subfamily A member 43 and cytochrome P450 family 3 subfamily A member 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%infection%" OR LOWER(efo_term) LIKE "%infection%") AND (LOWER(drugName) LIKE "%cobicistat%" OR LOWER(tradeNames_list) LIKE "%cobicistat%" OR LOWER(syns_list) LIKE "%cobicistat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1148789', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148800', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148809', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148810', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148820', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148821', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148822', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148832', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148833', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148842', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148843', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148853', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148854', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148855', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148864', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148865', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148866', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148875', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148876', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148877', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148886', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148888', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148897', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148898', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148899', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148908', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148910', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148919', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148920', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148921', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148930', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148931', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148932', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148941', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148942', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148943', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148887', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43'}, {'UUID': 'DrugTargetsIndication121923_text_1148831', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148799', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148787', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148777', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148776', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148909', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7'}, {'UUID': 'DrugTargetsIndication121923_text_1148844', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5'}, {'UUID': 'DrugTargetsIndication121923_text_1148811', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148798', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV-1 infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148788', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}, {'UUID': 'DrugTargetsIndication121923_text_1148778', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'syns_list': "['Cobicistat', 'Cobicistat on silicon dioxide', 'Cobicistat, (r,r,s)-GS-9350']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1263 | Q34 | What are the names of the genes that are targeted by the drug Progesterone in the treatment of amenorrhea? | In the context of amenorrhea, the drug Progesterone targets the gene progesterone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%amenorrhea%" OR LOWER(efo_term) LIKE "%amenorrhea%") AND (LOWER(drugName) LIKE "%progesterone%" OR LOWER(tradeNames_list) LIKE "%progesterone%" OR LOWER(syns_list) LIKE "%progesterone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_940055', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'syns_list': "['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amenorrhea', 'efo_term': 'amenorrhea', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940099', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'syns_list': "['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amenorrhea', 'efo_term': 'amenorrhea', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940143', 'drugName': 'Progesterone', 'tradeNames_list': "['Crinone', 'Cyclogest', 'Endometrin', 'Gesterol', 'Lutigest', 'MilprosaProchieve', 'Progesta-care', 'Progestasert', 'Progesterone', 'ProgestinPrometrium', 'Regumate', 'Serenity for women', 'Syngestrone', 'Utrogestan']", 'syns_list': "['NSC-64377', 'NSC-9704', 'Progesterone', 'Progesterone, micronizedProgesteronum', 'U 3672']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Amenorrhea', 'efo_term': 'amenorrhea', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.310 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Stevens-Johnson syndrome? | In the context of Stevens-Johnson syndrome, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stevens-johnson syndrome%" OR LOWER(efo_term) LIKE "%stevens-johnson syndrome%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227766', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228621', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228906', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229191', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229761', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230046', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230901', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231186', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231471', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231756', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230616', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228336', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227196', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226626', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226341', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232041', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229476', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228051', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227481', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226911', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.434 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol in the treatment of hypertension? | In the context of hypertension, the drug Carvedilol targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%carvedilol%" OR LOWER(tradeNames_list) LIKE "%carvedilol%" OR LOWER(syns_list) LIKE "%carvedilol%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_359313', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357649', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358673', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_356977', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357905', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_359793', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_357329', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357617', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358257', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358385', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358737', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358929', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357809', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_359537', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359473', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359601', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359633', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359921', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359825', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_357969', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357041', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357265', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358129', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357393', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358353', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358289', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358481', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358897', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357073', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358769', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357745', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358993', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357521', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359057', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359089', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359729', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359345', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359505', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357105', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359697', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359569', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359665', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_357297', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360049', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359761', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359889', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359857', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360017', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_357137', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359985', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359953', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_357361', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358033', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357585', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358193', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358097', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358161', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358609', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357681', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358321', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357425', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358577', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358417', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358545', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358513', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_359217', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357201', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358705', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357713', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358865', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357489', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358833', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358801', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_359185', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357777', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358961', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357233', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359153', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359025', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359121', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357553', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360081', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359281', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359409', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_359377', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_360145', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_360113', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_359249', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_358641', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_358225', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358065', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_358001', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357841', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357169', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_358449', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_357009', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_359441', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_357937', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_357457', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_357873', 'drugName': 'Carvedilol', 'tradeNames_list': "['Carvedilol', 'Coreg', 'Coreg CR', 'Eucardic 12.5', 'Eucardic 25Eucardic 3.125', 'Eucardic 6.25']", 'syns_list': "['BM 14.190', 'BM-14-190', 'BM-14.190', 'BM-14190', 'C07AG02', 'CarvedilolCoronis', 'DQ-2466', 'Dilatrend', 'Dimitone', 'Eucardic', 'Korvasan', 'KredexNSC-758694', 'SKF-105517', 'Talliton']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.665 | Q34 | What are the names of the genes that are targeted by the drug Roflumilast in the treatment of Airway obstruction? | In the context of Airway obstruction, the drug Roflumilast targets the gene phosphodiesterase 4A, phosphodiesterase 4D, phosphodiesterase 4B and phosphodiesterase 4C. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%airway obstruction%" OR LOWER(efo_term) LIKE "%airway obstruction%") AND (LOWER(drugName) LIKE "%roflumilast%" OR LOWER(tradeNames_list) LIKE "%roflumilast%" OR LOWER(syns_list) LIKE "%roflumilast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_695489', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695552', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695573', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695594', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695636', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695657', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695678', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695720', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695741', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695762', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695783', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695825', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695846', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695867', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695888', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695909', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695930', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695951', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695972', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695993', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696014', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696056', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696077', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696098', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696119', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696140', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696182', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696203', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696224', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696245', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_696266', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696287', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696308', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696329', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696350', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696371', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696392', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696413', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696434', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696455', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696476', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696497', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696518', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696539', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4C', 'approvedName': 'phosphodiesterase 4C'}, {'UUID': 'DrugTargetsIndication121923_text_696035', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695699', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695531', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695447', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695405', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695384', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_696161', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4B', 'approvedName': 'phosphodiesterase 4B'}, {'UUID': 'DrugTargetsIndication121923_text_695804', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4D', 'approvedName': 'phosphodiesterase 4D'}, {'UUID': 'DrugTargetsIndication121923_text_695615', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695510', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695468', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}, {'UUID': 'DrugTargetsIndication121923_text_695426', 'drugName': 'Roflumilast', 'tradeNames_list': "['Daliresp', 'Daxas', 'Zoryve']", 'syns_list': "['Arq-151', 'B-9302-107', 'B9302-107', 'BY-217', 'BY217', 'BYK-20869BYK20869', 'Roflumilast', 'Zoryve']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lung Diseases, Obstructive', 'efo_term': 'Airway obstruction', 'approvedSymbol': 'PDE4A', 'approvedName': 'phosphodiesterase 4A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.372 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of atopic eczema? | In the context of atopic eczema, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%atopic eczema%" OR LOWER(efo_term) LIKE "%atopic eczema%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218667', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219291', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219499', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219707', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220123', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220331', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220539', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240811', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240893', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240975', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241057', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241221', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241303', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241385', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241467', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241549', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241631', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241713', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241795', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241877', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243801', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'syns_list': "['Cortisol 17-butyrate', 'Hydrocortisone 17-butyrateHydrocortisone butyrate', 'Hydrocortisone-17-butyrate', 'NSC-758433']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243805', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'syns_list': "['Cortisol 17-butyrate', 'Hydrocortisone 17-butyrateHydrocortisone butyrate', 'Hydrocortisone-17-butyrate', 'NSC-758433']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220747', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219083', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218251', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217835', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217627', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241139', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219915', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218875', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218459', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218043', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dermatitis, Atopic', 'efo_term': 'atopic eczema', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.570 | Q34 | What are the names of the genes that are targeted by the drug Lidocaine in the treatment of sunburn? | In the context of sunburn, the drug Lidocaine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sunburn%" OR LOWER(efo_term) LIKE "%sunburn%") AND (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_list) LIKE "%lidocaine%" OR LOWER(syns_list) LIKE "%lidocaine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_638359', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638704', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638819', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638934', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_639164', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639279', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639394', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639624', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639739', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_639854', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639969', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640199', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640314', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640429', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_640544', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640659', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640774', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_640889', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641004', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641119', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_641234', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641464', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641579', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641694', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641809', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_641924', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642154', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642269', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642384', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642499', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_642614', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642729', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642844', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_642959', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643074', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643189', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_643304', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643419', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643534', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643649', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643764', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643879', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_643994', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644109', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644224', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644339', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644454', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_644569', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_641349', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_639509', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_638589', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638129', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637899', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_637784', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_642039', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_640084', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_639049', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638474', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_638244', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_638014', 'drugName': 'Lidocaine', 'tradeNames_list': "['Alphacaine', 'Anestacon', 'Dentipatch', 'Lidocaine', 'LidodermLignocaine Hcl', 'Lignostab', 'Lmx 4', 'Oraqix', 'Vagisil', 'XylocaineXylodase', 'Xylotox', 'Ztlido']", 'syns_list': "['ALGRX 3268', 'ALGRX-3268', 'Anestacon', 'Embolex', 'Iontocaine', 'LidocaineLidocainum', 'Lidocaton', 'Lidopen', 'Lignocaine', 'NSC-40030', 'OctocaineSolarcaine', 'Xylestesin']", 'yearOfFirstApproval': 1948, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sunburn', 'efo_term': 'sunburn', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.944 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of migraine disorder? | In the context of migraine disorder, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%migraine disorder%" OR LOWER(efo_term) LIKE "%migraine disorder%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840175', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840412', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840491', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840570', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840728', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840807', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840886', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841044', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841123', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841202', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841281', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841439', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841518', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841597', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841676', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841755', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840965', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840333', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840017', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839859', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839780', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841360', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840649', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840254', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840096', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839938', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Migraine Disorders', 'efo_term': 'migraine disorder', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.183 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218065', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218474', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218481', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218682', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218890', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218897', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219098', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219306', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219313', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219514', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219521', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219729', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219930', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219937', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220138', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220145', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220346', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220353', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220554', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220561', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220762', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220769', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219105', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218273', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217857', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217649', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217642', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219722', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218689', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218266', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218058', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217850', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.994 | Q34 | What are the names of the genes that are targeted by the drug Solifenacin Succinate in the treatment of overactive bladder? | In the context of overactive bladder, the drug Solifenacin Succinate targets the gene cholinergic receptor muscarinic 3 and cholinergic receptor muscarinic 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%overactive bladder%" OR LOWER(efo_term) LIKE "%overactive bladder%") AND (LOWER(drugName) LIKE "%solifenacin succinate%" OR LOWER(tradeNames_list) LIKE "%solifenacin succinate%" OR LOWER(syns_list) LIKE "%solifenacin succinate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857280', 'drugName': 'Solifenacin Succinate', 'tradeNames_list': "['Solifenacin succinate', 'Vesicare', 'Vesicare ls']", 'syns_list': "['Solifenacin succinate', 'YM-67905', 'YM-905', 'YM67905', 'YM905']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}, {'UUID': 'DrugTargetsIndication121923_text_857283', 'drugName': 'Solifenacin Succinate', 'tradeNames_list': "['Solifenacin succinate', 'Vesicare', 'Vesicare ls']", 'syns_list': "['Solifenacin succinate', 'YM-67905', 'YM-905', 'YM67905', 'YM905']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder, Overactive', 'efo_term': 'overactive bladder', 'approvedSymbol': 'CHRM2', 'approvedName': 'cholinergic receptor muscarinic 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.626 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib Tosylate in the treatment of clear cell renal carcinoma? | In the context of clear cell renal carcinoma, the drug Sorafenib Tosylate targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%clear cell renal carcinoma%" OR LOWER(efo_term) LIKE "%clear cell renal carcinoma%") AND (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_list) LIKE "%sorafenib tosylate%" OR LOWER(syns_list) LIKE "%sorafenib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683537', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683720', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683781', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683842', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683964', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684025', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684086', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684208', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684269', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684330', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684391', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684513', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684574', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684635', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684696', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684757', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684818', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684879', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684940', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685001', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685062', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685184', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685245', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685306', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685367', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685428', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685550', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685611', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685672', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685733', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685794', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685855', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685916', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685123', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684147', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683659', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683415', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683293', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683232', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685489', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684452', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683903', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683598', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683476', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683354', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'clear cell renal carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.951 | Q34 | What are the names of the genes that are targeted by the drug Meloxicam in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Meloxicam targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%meloxicam%" OR LOWER(tradeNames_list) LIKE "%meloxicam%" OR LOWER(syns_list) LIKE "%meloxicam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_842373', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842418', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842433', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842448', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842478', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842493', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842508', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842538', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842523', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842403', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842343', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842298', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842313', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842463', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842388', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842358', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_842328', 'drugName': 'Meloxicam', 'tradeNames_list': "['Anjeso', 'Meloxicam', 'Mobic', 'Qmiiz odt', 'Vivlodex']", 'syns_list': "['Acticam', 'Contacera', 'Coxicam', 'Emdocam', 'Flexicam', 'Inflacam', 'LoxicomMelfax', 'Melosus', 'Melovem', 'Meloxicam', 'Meloxidolor', 'MeloxidylMeloxivet', 'Meloxoral', 'Metacam', 'Movatec', 'N-1539', 'N1539', 'RecocamRevitacam', 'Rheumocam', 'UH-AC 62XX', 'UH-AC-62 XX', 'UHAC-62XX']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1673 | Q34 | What are the names of the genes that are targeted by the drug Berotralstat Hydrochloride in the treatment of hereditary angioedema? | In the context of hereditary angioedema, the drug Berotralstat Hydrochloride targets the gene kallikrein B1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hereditary angioedema%" OR LOWER(efo_term) LIKE "%hereditary angioedema%") AND (LOWER(drugName) LIKE "%berotralstat hydrochloride%" OR LOWER(tradeNames_list) LIKE "%berotralstat hydrochloride%" OR LOWER(syns_list) LIKE "%berotralstat hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095501', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095504', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095505', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095506', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095503', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095499', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095497', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095496', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095507', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095502', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095500', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}, {'UUID': 'DrugTargetsIndication121923_text_1095498', 'drugName': 'Berotralstat Hydrochloride', 'tradeNames_list': "['Orladeyo']", 'syns_list': "['BCX7353.2HCl', 'Berotralstat dihydrochlorideBerotralstat hydrochloride']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedemas, Hereditary', 'efo_term': 'hereditary angioedema', 'approvedSymbol': 'KLKB1', 'approvedName': 'kallikrein B1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.916 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of common cold? | In the context of common cold, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%common cold%" OR LOWER(efo_term) LIKE "%common cold%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838546', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838669', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838710', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838751', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838833', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838874', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838915', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838997', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839038', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839079', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839120', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839202', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839243', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839284', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839325', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839366', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839407', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839448', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839489', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839530', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839571', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839653', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839694', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839612', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838956', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838628', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838382', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838341', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838464', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839161', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838792', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838587', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838505', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838423', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Common Cold', 'efo_term': 'common cold', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1824 | Q34 | What are the names of the genes that are targeted by the drug Golodirsen in the treatment of Duchenne muscular dystrophy? | In the context of Duchenne muscular dystrophy, the drug Golodirsen targets the gene dystrophin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%duchenne muscular dystrophy%" OR LOWER(efo_term) LIKE "%duchenne muscular dystrophy%") AND (LOWER(drugName) LIKE "%golodirsen%" OR LOWER(tradeNames_list) LIKE "%golodirsen%" OR LOWER(syns_list) LIKE "%golodirsen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100518', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100522', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100514', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100510', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100508', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100520', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100516', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}, {'UUID': 'DrugTargetsIndication121923_text_1100512', 'drugName': 'Golodirsen', 'tradeNames_list': "['Vyondys 53']", 'syns_list': "['Golodirsen', 'NG-12-0163', 'SRP-4053']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscular Dystrophy, Duchenne', 'efo_term': 'Duchenne muscular dystrophy', 'approvedSymbol': 'DMD', 'approvedName': 'dystrophin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1062 | Q34 | What are the names of the genes that are targeted by the drug Imiquimod in the treatment of basal cell carcinoma? | In the context of basal cell carcinoma, the drug Imiquimod targets the gene toll like receptor 7. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%basal cell carcinoma%" OR LOWER(efo_term) LIKE "%basal cell carcinoma%") AND (LOWER(drugName) LIKE "%imiquimod%" OR LOWER(tradeNames_list) LIKE "%imiquimod%" OR LOWER(syns_list) LIKE "%imiquimod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_919623', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919727', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919729', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919780', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919833', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919835', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919886', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919939', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919941', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919992', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919994', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920047', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920098', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920100', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920151', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920153', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920204', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920206', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920257', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920259', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920310', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920312', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919888', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919676', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919570', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919517', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919515', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_920045', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919782', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'skin basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919674', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919621', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}, {'UUID': 'DrugTargetsIndication121923_text_919568', 'drugName': 'Imiquimod', 'tradeNames_list': "['Aldara', 'Imiquimod', 'Zyclara']", 'syns_list': "['Aldara', 'Imiquimod', 'NSC-369100', 'NSC-759651', 'R-837', 'S-26308', 'S26308Tmx-101']", 'yearOfFirstApproval': 1997, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Basal Cell', 'efo_term': 'basal cell carcinoma', 'approvedSymbol': 'TLR7', 'approvedName': 'toll like receptor 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.298 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227753', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228608', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228893', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229178', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229748', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230033', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230888', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231173', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231458', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231743', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232313', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230603', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227183', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226613', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226328', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232028', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229463', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228038', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227468', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226898', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1672 | Q34 | What are the names of the genes that are targeted by the drug Tazemetostat Hydrobromide in the treatment of follicular lymphoma? | In the context of follicular lymphoma, the drug Tazemetostat Hydrobromide targets the gene enhancer of zeste 2 polycomb repressive complex 2 subunit. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%follicular lymphoma%" OR LOWER(efo_term) LIKE "%follicular lymphoma%") AND (LOWER(drugName) LIKE "%tazemetostat hydrobromide%" OR LOWER(tradeNames_list) LIKE "%tazemetostat hydrobromide%" OR LOWER(syns_list) LIKE "%tazemetostat hydrobromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095405', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095414', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095417', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095420', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095426', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095429', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095432', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095438', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095441', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095444', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095447', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095453', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095456', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095459', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095462', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095465', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095468', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095471', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095474', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095477', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095480', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095486', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095489', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095492', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095495', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095483', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095411', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095399', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095393', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095390', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095435', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095450', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095423', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095408', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095402', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}, {'UUID': 'DrugTargetsIndication121923_text_1095396', 'drugName': 'Tazemetostat Hydrobromide', 'tradeNames_list': "['Tazverik']", 'syns_list': "['E-7438 HYDROBROMIDE', 'EPZ-6438 HYDROBROMIDE', 'EPZ-6438 MONOHYDROBROMIDEEZ-438', 'EZ438', 'Tazemetostat hydrobromideTazemetostat monohydrobromide']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Follicular', 'efo_term': 'follicular lymphoma', 'approvedSymbol': 'EZH2', 'approvedName': 'enhancer of zeste 2 polycomb repressive complex 2 subunit'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.465 | Q34 | What are the names of the genes that are targeted by the drug Carvedilol Phosphate in the treatment of myocardial infarction? | In the context of myocardial infarction, the drug Carvedilol Phosphate targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D and adrenoceptor alpha 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myocardial infarction%" OR LOWER(efo_term) LIKE "%myocardial infarction%") AND (LOWER(drugName) LIKE "%carvedilol phosphate%" OR LOWER(tradeNames_list) LIKE "%carvedilol phosphate%" OR LOWER(syns_list) LIKE "%carvedilol phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_416729', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416741', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416745', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416749', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416757', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416761', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416765', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416773', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416777', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416781', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416785', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416793', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416797', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416801', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416805', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416809', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416813', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416817', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416821', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416825', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416829', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416837', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416841', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416845', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416849', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416853', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416861', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416865', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416869', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416873', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416877', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416881', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416885', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416889', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416893', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416897', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416901', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416905', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416909', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416913', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416917', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416921', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416925', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416929', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416933', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416937', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416941', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416945', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_416949', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416953', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416957', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416965', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416969', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416973', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416977', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416981', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416985', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416993', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416997', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417001', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417005', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417009', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417013', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417017', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417021', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417025', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_417029', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417033', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417037', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417041', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417045', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417049', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417053', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417057', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417061', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417065', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417069', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417073', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417077', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417081', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417085', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417089', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417093', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417097', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417101', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_417105', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1D', 'approvedName': 'adrenoceptor alpha 1D'}, {'UUID': 'DrugTargetsIndication121923_text_416961', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416833', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416769', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416737', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416721', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416713', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416709', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416989', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB3', 'approvedName': 'adrenoceptor beta 3'}, {'UUID': 'DrugTargetsIndication121923_text_416857', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416789', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2'}, {'UUID': 'DrugTargetsIndication121923_text_416753', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416733', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416725', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_416717', 'drugName': 'Carvedilol Phosphate', 'tradeNames_list': "['Coreg cr']", 'syns_list': "['Carvedilol phosphate', 'Carvedilol phosphate hemihydrateCarvedilol phosphate hydrate', 'SK&F-105517-D', 'SKF 105517DSKF-105517D']", 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myocardial Infarction', 'efo_term': 'myocardial infarction', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1296 | Q34 | What are the names of the genes that are targeted by the drug Dasiglucagon Hydrochloride in the treatment of Hypoglycemia? | In the context of Hypoglycemia, the drug Dasiglucagon Hydrochloride targets the gene glucagon receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypoglycemia%" OR LOWER(efo_term) LIKE "%hypoglycemia%") AND (LOWER(drugName) LIKE "%dasiglucagon hydrochloride%" OR LOWER(tradeNames_list) LIKE "%dasiglucagon hydrochloride%" OR LOWER(syns_list) LIKE "%dasiglucagon hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_968350', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968352', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypoglycemia', 'efo_term': 'Hypoglycemia', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1309 | Q34 | What are the names of the genes that are targeted by the drug Nitroglycerin in the treatment of pain? | In the context of pain, the drug Nitroglycerin targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_list) LIKE "%nitroglycerin%" OR LOWER(syns_list) LIKE "%nitroglycerin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972650', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972718', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972582', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_972514', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972480', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972684', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1'}, {'UUID': 'DrugTargetsIndication121923_text_972616', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2'}, {'UUID': 'DrugTargetsIndication121923_text_972548', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'syns_list': "['C01DA02', 'Chlormethine oxide hydrochloride', 'Diluted nitroglycerinGlonoinum', 'Glyceryl Trinitrate', 'Glyceryl trinitrateGlyceryl trinitrate solution', 'Imx-150', 'Mechlorethamine oxide hclMitomen', 'Mustron', 'Nitora', 'Nitroglycerin', 'Nitroglycerin tabletsNitromin hydrochloride', 'Transderm-Nitro', 'TrinitrinTrinitrin tablets', 'Trinitrine']", 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.379 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone in the treatment of Herpes Labialis? | In the context of Herpes Labialis, the drug Hydrocortisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%herpes labialis%" OR LOWER(efo_term) LIKE "%herpes labialis%") AND (LOWER(drugName) LIKE "%hydrocortisone%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone%" OR LOWER(syns_list) LIKE "%hydrocortisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_241228', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241474', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241556', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241638', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241802', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241884', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241392', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241064', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240900', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240818', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241720', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241310', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_241146', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_240982', 'drugName': 'Hydrocortisone', 'tradeNames_list': "['Acetasol hc', 'Acticort', 'Aeroseb-hc', 'Ala-cort', 'Ala-scalpAlkindi sprinkle', 'Alphaderm', 'Anflam', 'Anucort-Hc', 'Anugesic hcAnusol hc', 'Anusol plus hc', 'Anusol soothing relief', 'Anusol-HcBalneol-hc', 'Beta-hc', 'Calmurid hc', 'Canesten hc', 'Cetacort', 'Cipro hcCobadex', 'Colocort', 'Corlan', 'Cort-dome', 'Cortef', 'Cortenem', 'CortenemaCortril', 'Daktacort', 'Daktacort hydrocort', 'Derma care hydrocortDermacort', 'Dermaspray demang', 'Dioderm', 'Dome-cort', 'EconacortEfcortelan p', 'Eldecort', 'Epicort', 'Eurax-hc', 'Eurax-hydrocortEvacort', 'Exe-cort', 'Flexicort', 'Germoloids hc', 'Glycort', 'GregodermH-cort', 'Hc #1', 'Hc #4', 'Hc (hydrocortisone)', 'Hi-cor', 'Hydro-rxHydrocort in calamine oily', 'Hydrocort in cetomacrogol for aHydrocort in wte soft paraf', 'HydrocortisoneHydrocortisone in absorbase', 'Hydrocortone', 'Hydroderm', 'Hydroderm hcHytone', 'Jungle for', 'Locoid', 'Medicort', 'Mildison lipocreamNogenic hc', 'Nutracort', 'Nybadex', 'Nystaform-hc', 'Otoseptil', 'OtosporinPenecort', 'Perinal', 'Plenadren', 'Proctocort', 'Proctocream hcProctofoam hc', 'Proctosedyl', 'Quinocort', 'Sential hc', 'Stie-cortSynacort', 'Terra-cortril nystatin', 'Texacort', 'Timocort', 'TimodineTopisone', 'Tri-cicatrin', 'Uniroid', 'Uniroid hc', 'Xyloproct', 'Zenoxone']", 'syns_list': "['Cor-Oticin', 'Cortifoam', 'Cortisol', 'FLEXICORT', 'HydrocortisoneMicort-HC', 'NSC-10483', 'Neo-Cortef', 'Ophthocort', 'Terra-CortrilU-Cort']", 'yearOfFirstApproval': 1952, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Herpes Labialis', 'efo_term': 'Herpes Labialis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1090 | Q34 | What are the names of the genes that are targeted by the drug Apalutamide in the treatment of prostate carcinoma? | In the context of prostate carcinoma, the drug Apalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate carcinoma%" OR LOWER(efo_term) LIKE "%prostate carcinoma%") AND (LOWER(drugName) LIKE "%apalutamide%" OR LOWER(tradeNames_list) LIKE "%apalutamide%" OR LOWER(syns_list) LIKE "%apalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921871', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921890', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921891', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921900', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921910', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921911', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921920', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921930', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921931', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921940', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921941', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921951', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921960', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921961', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921921', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921881', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921861', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921851', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921850', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921950', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921901', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921880', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921870', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921860', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.107 | Q34 | What are the names of the genes that are targeted by the drug Ondansetron in the treatment of Chemotherapy-induced nausea and vomiting? | In the context of Chemotherapy-induced nausea and vomiting, the drug Ondansetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chemotherapy-induced nausea and vomiting%" OR LOWER(efo_term) LIKE "%chemotherapy-induced nausea and vomiting%") AND (LOWER(drugName) LIKE "%ondansetron%" OR LOWER(tradeNames_list) LIKE "%ondansetron%" OR LOWER(syns_list) LIKE "%ondansetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205942', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205982', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205902', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205862', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205861', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205981', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205941', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205901', 'drugName': 'Ondansetron', 'tradeNames_list': "['Ondansetron', 'Zofran', 'Zofran odt', 'Zuplenz']", 'syns_list': "['A04AA01', 'Desmethylondansetron', 'EUR-1025', 'GR-38032', 'GR-38032FNSC-757870', 'Ondansetron', 'Zofran']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.128 | Q34 | What are the names of the genes that are targeted by the drug Levomilnacipran Hydrochloride in the treatment of major depressive disorder? | In the context of major depressive disorder, the drug Levomilnacipran Hydrochloride targets the gene solute carrier family 6 member 4 and solute carrier family 6 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%major depressive disorder%" OR LOWER(efo_term) LIKE "%major depressive disorder%") AND (LOWER(drugName) LIKE "%levomilnacipran hydrochloride%" OR LOWER(tradeNames_list) LIKE "%levomilnacipran hydrochloride%" OR LOWER(syns_list) LIKE "%levomilnacipran hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_206894', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206906', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206910', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206914', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206922', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206926', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206930', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206938', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206942', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206946', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206950', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206958', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206962', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206966', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206934', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206902', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206886', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206878', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206874', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206954', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_206918', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206898', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206890', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}, {'UUID': 'DrugTargetsIndication121923_text_206882', 'drugName': 'Levomilnacipran Hydrochloride', 'tradeNames_list': "['Fetzima']", 'syns_list': "['(1s,2r)-milnacipran hydrochloride', 'F 2695 HYDROCHLORIDEF-2695 HYDROCHLORIDE', 'F2695', 'F2695 HYDROCHLORIDELevomilnacipran hydrochloride']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder, Major', 'efo_term': 'major depressive disorder', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1119 | Q34 | What are the names of the genes that are targeted by the drug Levothyroxine Sodium in the treatment of differentiated thyroid carcinoma? | In the context of differentiated thyroid carcinoma, the drug Levothyroxine Sodium targets the gene thyroid hormone receptor alpha and thyroid hormone receptor beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%differentiated thyroid carcinoma%" OR LOWER(efo_term) LIKE "%differentiated thyroid carcinoma%") AND (LOWER(drugName) LIKE "%levothyroxine sodium%" OR LOWER(tradeNames_list) LIKE "%levothyroxine sodium%" OR LOWER(syns_list) LIKE "%levothyroxine sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924835', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924856', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924863', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924870', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924884', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924891', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924898', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924912', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924919', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924926', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924933', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924947', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924954', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924961', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924968', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924975', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924982', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924989', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924996', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925003', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925010', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925024', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925031', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925038', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925045', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925052', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925066', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925073', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925080', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925087', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925094', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925101', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925108', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925115', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925122', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925129', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925136', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925143', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925150', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925157', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925164', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925171', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925178', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925185', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925192', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925199', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925206', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925213', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925220', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925227', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925234', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925248', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925255', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925262', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925269', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925276', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925283', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925297', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925304', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925311', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925318', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925325', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925332', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925339', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925346', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925353', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925360', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925367', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925374', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925381', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925388', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925395', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925402', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925409', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925416', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925423', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925430', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925437', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925444', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925451', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925458', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925465', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925472', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925479', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925486', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925493', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925241', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925017', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924905', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924849', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924821', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924807', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924800', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925290', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_925059', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924940', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924877', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924842', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924828', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_924814', 'drugName': 'Levothyroxine Sodium', 'tradeNames_list': "['Eltroxin', 'Ermeza', 'Euthyrox', 'Evotrox', 'L-thyroxine henning', 'Levo-tLevolet', 'Levothroid', 'Levothyroid', 'Levothyroxine sodium', 'LevoxineLevoxyl', 'Novothyrox', 'Soloxine', 'Synthroid', 'Thyquidity', 'Thyro-tabsThyrol L', 'Thyroxine', 'Tirosint', 'Tirosint-sol', 'Unithroid']", 'syns_list': "['Eferox', 'Levaxin', 'Levothyrox', 'Levothyroxine sodiumLevothyroxine sodium anhydrous', 'Levothyroxine sodium hydrateLevothyroxine sodium pentahydrate', 'Levothyroxinum natricum anhydrousLiotrix (t4)', 'Monosodium l-thyroxine hydrate', 'NSC-259940', 'OroxineSodium levothyroxine pentahydrate', 'Soloxine', 'T4', 'T4 (liotrix)Thyroxine', 'Thyroxine sodium', 'Thyroxine sodium salt']", 'yearOfFirstApproval': 2000, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'differentiated thyroid carcinoma', 'approvedSymbol': 'THRA', 'approvedName': 'thyroid hormone receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.939 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of influenza? | In the context of influenza, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%influenza%" OR LOWER(efo_term) LIKE "%influenza%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840170', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840407', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840486', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840565', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840723', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840802', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840881', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841039', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841118', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841197', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841276', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841434', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841513', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841592', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841671', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841750', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840960', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840328', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840012', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839854', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839775', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841355', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840644', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840249', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840091', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839933', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Influenza, Human', 'efo_term': 'influenza', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.357 | Q34 | What are the names of the genes that are targeted by the drug Fluticasone Propionate in the treatment of Nasal polyposis? | In the context of Nasal polyposis, the drug Fluticasone Propionate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nasal polyposis%" OR LOWER(efo_term) LIKE "%nasal polyposis%") AND (LOWER(drugName) LIKE "%fluticasone propionate%" OR LOWER(tradeNames_list) LIKE "%fluticasone propionate%" OR LOWER(syns_list) LIKE "%fluticasone propionate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_232527', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232608', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232635', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232662', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232716', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232743', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232770', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232824', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232851', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232878', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232905', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232959', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232986', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233013', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233040', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233067', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233094', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233121', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233148', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233175', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233202', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233256', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233283', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233310', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233337', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233364', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233418', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233445', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233472', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233499', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233526', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233553', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233580', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233607', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233634', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233661', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233688', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233715', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233742', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233769', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233796', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233823', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233850', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233877', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233904', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233931', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233958', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233985', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234012', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234039', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234066', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234120', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234147', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234174', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234201', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234228', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234255', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234309', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234336', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234363', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234390', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234417', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234444', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234471', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234498', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234525', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234552', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234579', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234606', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234633', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234660', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234687', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234714', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234741', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234768', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234795', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234822', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234849', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234876', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234903', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234930', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234957', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234984', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235011', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235038', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_235065', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234093', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233229', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232797', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232581', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232473', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232419', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232392', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_234282', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_233391', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232932', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232689', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232554', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232500', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232446', 'drugName': 'Fluticasone Propionate', 'tradeNames_list': "['Aerivio spiromax', 'Airflusal forspiro', 'Armonair digihalerArmonair respiclick', 'Cutivate', 'Flixonase', 'Flixotide', 'FlonaseFlonase allergy relief', 'Flovent', 'Flovent diskus 100Flovent diskus 250', 'Flovent diskus 50', 'Flovent hfaFluticasone propionate', 'Flutiform', 'Nasofan', 'Pirinase', 'SerefloSeretide 100', 'Seretide 125', 'Seretide 250', 'Seretide 50', 'Seretide 500Sirdupla', 'Xhance']", 'syns_list': "['CCI 18781', 'CCI-18781', 'CCI18781', 'FLOVENT', 'Fluticaps', 'FluticasoneFluticasone propionate', 'Fluticasone propionate Fluticasone-17-propionate', 'NSC-759889', 'Opn-375', 'OptinosePF-00241939', 'R01AD08']", 'yearOfFirstApproval': 1990, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nasal Polyps', 'efo_term': 'Nasal polyposis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1714 | Q34 | What are the names of the genes that are targeted by the drug Elagolix Sodium in the treatment of endometriosis? | In the context of endometriosis, the drug Elagolix Sodium targets the gene gonadotropin releasing hormone receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%endometriosis%" OR LOWER(efo_term) LIKE "%endometriosis%") AND (LOWER(drugName) LIKE "%elagolix sodium%" OR LOWER(tradeNames_list) LIKE "%elagolix sodium%" OR LOWER(syns_list) LIKE "%elagolix sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097301', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097304', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097305', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097303', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097297', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097296', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097299', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097302', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097300', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1097298', 'drugName': 'Elagolix Sodium', 'tradeNames_list': "['Orilissa']", 'syns_list': "['Elagolix sodium', 'Elagolix sodium salt', 'NBI-56418 NA', 'NBI-56418-NAOrlissa']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Endometriosis', 'efo_term': 'endometriosis', 'approvedSymbol': 'GNRHR', 'approvedName': 'gonadotropin releasing hormone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.687 | Q34 | What are the names of the genes that are targeted by the drug Rivaroxaban in the treatment of pulmonary embolism? | In the context of pulmonary embolism, the drug Rivaroxaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary embolism%" OR LOWER(efo_term) LIKE "%pulmonary embolism%") AND (LOWER(drugName) LIKE "%rivaroxaban%" OR LOWER(tradeNames_list) LIKE "%rivaroxaban%" OR LOWER(syns_list) LIKE "%rivaroxaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708857', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708962', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708997', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709032', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709102', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709137', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709172', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709242', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709277', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709312', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709347', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709417', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709452', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709487', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709522', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709557', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709592', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709627', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709662', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709697', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709732', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709802', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709837', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709872', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709907', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709942', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710012', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710047', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710082', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710117', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710152', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710187', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710222', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710257', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710292', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709767', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709207', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708927', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708787', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708717', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708682', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709977', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709382', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_709067', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708892', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708822', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_708752', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'syns_list': "['BAY 59-7939', 'BAY-59-7939', 'JNJ-39039039', 'JNJ39039039', 'Rivaroxaban']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pulmonary Embolism', 'efo_term': 'pulmonary embolism', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.786 | Q34 | What are the names of the genes that are targeted by the drug Olaparib in the treatment of cancer? | In the context of cancer, the drug Olaparib targets the gene poly(ADP-ribose) polymerase 2, poly(ADP-ribose) polymerase 1 and poly(ADP-ribose) polymerase family member 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%olaparib%" OR LOWER(tradeNames_list) LIKE "%olaparib%" OR LOWER(syns_list) LIKE "%olaparib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_797332', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795456', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796528', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796796', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797600', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797868', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798006', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795259', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795996', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795460', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796599', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796863', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795590', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797537', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797470', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797667', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795661', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798002', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797872', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798073', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798136', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795121', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795188', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795058', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796130', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796059', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796260', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796733', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795393', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796662', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795527', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796997', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796867', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797001', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797064', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797738', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797336', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797533', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795192', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797734', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797604', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797671', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795657', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798270', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797805', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797939', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797935', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798207', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798069', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798203', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798140', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795728', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795795', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795255', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795925', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795125', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795862', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796394', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795992', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796126', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796063', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796331', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796193', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796327', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796264', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797202', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796465', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796595', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796532', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796729', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795326', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796666', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795523', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797198', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796800', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796934', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796930', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797135', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795594', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797131', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797068', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798274', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797269', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797403', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797399', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798341', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_798337', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797265', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796398', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795929', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795858', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795791', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795054', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795389', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796197', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795322', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797466', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_797801', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_796461', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}, {'UUID': 'DrugTargetsIndication121923_text_795724', 'drugName': 'Olaparib', 'tradeNames_list': "['Lynparza']", 'syns_list': "['AZ-2281', 'AZ2281', 'AZD-2281', 'AZD2281', 'KEYLYNK-010 COMPONENT OLAPARIBKU-0059436', 'KU-59436', 'NSC-747856', 'OLAPARIB COMPONENT OF KEYLYNK-010Olaparib']", 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'PARP2', 'approvedName': 'poly(ADP-ribose) polymerase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.840 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of hemorrhage? | In the context of hemorrhage, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhage%" OR LOWER(efo_term) LIKE "%hemorrhage%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833158', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833491', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833380', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832936', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833269', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833047', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832875', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833097', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833319', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833430', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832986', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833208', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Cerebral Hemorrhage', 'efo_term': 'intracerebral hemorrhage', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.211 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of choroiditis? | In the context of choroiditis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%choroiditis%" OR LOWER(efo_term) LIKE "%choroiditis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218717', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219341', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219549', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219757', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220173', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220381', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220589', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220797', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219133', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218301', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217885', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217677', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219965', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218925', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218509', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218093', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1392 | Q34 | What are the names of the genes that are targeted by the drug Fingolimod in the treatment of immune system disease? | In the context of immune system disease, the drug Fingolimod targets the gene sphingosine-1-phosphate receptor 5, sphingosine-1-phosphate receptor 2, sphingosine-1-phosphate receptor 4, sphingosine-1-phosphate receptor 3 and sphingosine-1-phosphate receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%immune system disease%" OR LOWER(efo_term) LIKE "%immune system disease%") AND (LOWER(drugName) LIKE "%fingolimod%" OR LOWER(tradeNames_list) LIKE "%fingolimod%" OR LOWER(syns_list) LIKE "%fingolimod%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1035403', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035454', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035471', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035488', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035522', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035539', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035556', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035590', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035607', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035624', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035641', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035675', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035692', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035709', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035726', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035743', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035760', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035777', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035794', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035811', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035828', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035862', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035879', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035896', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035913', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035930', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035964', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035981', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035998', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1036015', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1036032', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036049', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036066', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036083', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036100', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036117', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036134', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036151', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036168', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036185', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036202', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036219', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036236', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036253', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR3', 'approvedName': 'sphingosine-1-phosphate receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1036270', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036287', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036304', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036321', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036338', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036355', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036372', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036406', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036423', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036440', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036457', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036474', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1036491', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1035845', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035573', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035437', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035369', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035335', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035318', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1036389', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR1', 'approvedName': 'sphingosine-1-phosphate receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1035947', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR4', 'approvedName': 'sphingosine-1-phosphate receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1035658', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR2', 'approvedName': 'sphingosine-1-phosphate receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_1035505', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035420', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035386', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}, {'UUID': 'DrugTargetsIndication121923_text_1035352', 'drugName': 'Fingolimod', 'tradeNames_list': "['Gilenya']", 'syns_list': "['FTY-720', 'Fingolimod']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Immune System Diseases', 'efo_term': 'immune system disease', 'approvedSymbol': 'S1PR5', 'approvedName': 'sphingosine-1-phosphate receptor 5'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.142 | Q34 | What are the names of the genes that are targeted by the drug Osimertinib in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Osimertinib targets the gene epidermal growth factor receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%osimertinib%" OR LOWER(tradeNames_list) LIKE "%osimertinib%" OR LOWER(syns_list) LIKE "%osimertinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217149', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217155', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217157', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217159', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217163', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217165', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217167', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217171', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217173', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217185', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217197', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217221', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217233', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217245', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217257', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217269', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217281', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217293', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217305', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217317', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217329', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217353', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217365', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217377', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217389', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217341', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217153', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217145', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217141', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217139', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217169', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217209', 'drugName': 'Osimertinib', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291', 'AZD-9291 FREE BASE', 'AZD9291', 'Azd-9291', 'MereletinibOsimertinib']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217161', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217151', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217147', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_217143', 'drugName': 'Osimertinib Mesylate', 'tradeNames_list': "['Tagrisso']", 'syns_list': "['AZD-9291 MESYLATE', 'AZD9291 mesylate', 'Mereletinib mesilateMereletinib mesylate', 'Osimertinib mesilate', 'Osimertinib mesylate']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1894 | Q34 | What are the names of the genes that are targeted by the drug Torsemide in the treatment of stroke? | In the context of stroke, the drug Torsemide targets the gene solute carrier family 12 member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%stroke%" OR LOWER(efo_term) LIKE "%stroke%") AND (LOWER(drugName) LIKE "%torsemide%" OR LOWER(tradeNames_list) LIKE "%torsemide%" OR LOWER(syns_list) LIKE "%torsemide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149092', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1149100', 'drugName': 'Torsemide', 'tradeNames_list': "['Demadex', 'Soaanz', 'Torem 10', 'Torem 2.5', 'Torem 5', 'Torsemide']", 'syns_list': "['AC-4464', 'AC4464', 'BM-02.015', 'BM-02015', 'BM02.015', 'LupracTorasemide', 'Torasemide anhydrous', 'Torsemide', 'Upcard']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stroke', 'efo_term': 'stroke', 'approvedSymbol': 'SLC12A1', 'approvedName': 'solute carrier family 12 member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1324 | Q34 | What are the names of the genes that are targeted by the drug Venetoclax in the treatment of cancer? | In the context of cancer, the drug Venetoclax targets the gene BCL2 apoptosis regulator. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%venetoclax%" OR LOWER(tradeNames_list) LIKE "%venetoclax%" OR LOWER(syns_list) LIKE "%venetoclax%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_989692', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990148', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990604', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990224', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990186', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989768', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990642', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990566', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990946', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990528', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989806', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990984', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990756', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990452', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990072', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990718', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990490', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990338', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989730', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990870', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989920', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990908', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990376', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989844', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989958', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990414', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990034', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990262', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990110', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989882', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989996', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990300', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990680', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990832', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990794', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_991022', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990594', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_991012', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990138', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989910', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990670', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989720', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990404', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990860', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990252', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990746', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990822', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989796', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989948', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990176', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990898', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990290', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990632', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990708', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989986', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990366', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990784', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990328', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989682', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990214', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990442', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989758', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989834', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990024', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990062', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990936', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990974', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990480', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989872', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990518', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990556', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990100', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990530', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989884', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990112', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990568', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990606', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989770', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990150', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990682', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990720', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989922', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990758', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990188', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990796', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990226', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990834', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989732', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990644', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989808', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989960', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990264', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990872', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990910', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990302', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990340', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_989998', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990378', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990036', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}, {'UUID': 'DrugTargetsIndication121923_text_990416', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'syns_list': "['ABT-199', 'GDC-0199', 'RG-7601', 'RG7601', 'Venetoclax']", 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1048 | Q34 | What are the names of the genes that are targeted by the drug Pemetrexed Disodium in the treatment of non-small cell lung carcinoma? | In the context of non-small cell lung carcinoma, the drug Pemetrexed Disodium targets the gene thymidylate synthetase, phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase and dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%non-small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%non-small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%pemetrexed disodium%" OR LOWER(tradeNames_list) LIKE "%pemetrexed disodium%" OR LOWER(syns_list) LIKE "%pemetrexed disodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_918419', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918279', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918244', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'TYMS', 'approvedName': 'thymidylate synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918349', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}, {'UUID': 'DrugTargetsIndication121923_text_918384', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_918314', 'drugName': 'Pemetrexed Disodium', 'tradeNames_list': "['Alimta']", 'syns_list': "['LY-231514 DISODIUM SALT', 'LY231514 DISODIUM SALT', 'Pemetrexed disodiumPemetrexed disodium heptahydrate', 'Pemetrexed sodium hydratePemetrexed sodium salt']", 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Non-Small-Cell Lung', 'efo_term': 'non-small cell lung carcinoma', 'approvedSymbol': 'GART', 'approvedName': 'phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1560 | Q34 | What are the names of the genes that are targeted by the drug Ambrisentan in the treatment of pulmonary hypertension? | In the context of pulmonary hypertension, the drug Ambrisentan targets the gene endothelin receptor type A and endothelin receptor type B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary hypertension%" OR LOWER(efo_term) LIKE "%pulmonary hypertension%") AND (LOWER(drugName) LIKE "%ambrisentan%" OR LOWER(tradeNames_list) LIKE "%ambrisentan%" OR LOWER(syns_list) LIKE "%ambrisentan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084075', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084098', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084099', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084110', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084122', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084123', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084134', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084146', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084147', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084158', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084159', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084171', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084182', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084183', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084135', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084087', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084063', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084051', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084050', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084170', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRB', 'approvedName': 'endothelin receptor type B'}, {'UUID': 'DrugTargetsIndication121923_text_1084111', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084086', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084074', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}, {'UUID': 'DrugTargetsIndication121923_text_1084062', 'drugName': 'Ambrisentan', 'tradeNames_list': "['Letairis', 'Volibris']", 'syns_list': "['Ambrisentan', 'GSK-1325760', 'GSK-1325760A', 'GSK1325760', 'GSK1325760ALU-208075']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary hypertension', 'approvedSymbol': 'EDNRA', 'approvedName': 'endothelin receptor type A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1487 | Q34 | What are the names of the genes that are targeted by the drug Methotrexate in the treatment of psoriasis? | In the context of psoriasis, the drug Methotrexate targets the gene dihydrofolate reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%psoriasis%" OR LOWER(efo_term) LIKE "%psoriasis%") AND (LOWER(drugName) LIKE "%methotrexate%" OR LOWER(tradeNames_list) LIKE "%methotrexate%" OR LOWER(syns_list) LIKE "%methotrexate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1057114', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057427', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057436', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057588', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057749', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057758', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057910', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058071', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058080', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058232', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058241', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058402', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058554', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058563', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058715', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058724', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058876', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058885', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059037', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059046', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059198', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059359', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059368', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059520', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059529', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059681', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059842', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059851', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060003', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060012', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060164', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060173', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060325', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060334', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060486', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060495', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060647', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060656', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060808', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060817', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060969', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1060978', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061130', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061139', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061291', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061300', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061452', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061461', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061613', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061622', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061774', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061935', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061944', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062096', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062105', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062257', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062266', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062427', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062579', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062588', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062740', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062749', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062901', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062910', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063062', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063071', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063223', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063232', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063384', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063393', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063545', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063554', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063706', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063715', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063867', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1063876', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064028', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064037', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064189', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064198', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064350', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064359', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064511', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064520', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064672', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1064681', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1061783', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059207', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057919', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057275', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056953', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056792', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056783', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1062418', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1059690', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1058393', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057597', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis vulgaris', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057266', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1057105', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1056944', 'drugName': 'Methotrexate', 'tradeNames_list': "['Amethopterin', 'Ebetrex', 'Emtexate high-pot', 'Emtexate pf', 'FolexMaxtrex', 'Methotrexate', 'Metoject', 'Mexate', 'Otrexup', 'Otrexup pfsRasuvo', 'Reditrex', 'Rheumatrex', 'Trexall', 'Zlatal']", 'syns_list': "['(r)-methotrexate', 'ADX-2191', 'Abitrexate', 'Amethopterin', 'CL 14377CL-14377', 'D-amethopterin', 'D-methotrexate', 'EMT-25299', 'FolexMethotrexate', 'Methotrexate, (r)-', 'Methotrexate, d-', 'MethotrexatumMethylaminopterin', 'Mexate', 'Mexate-AQ', 'NSC-740', 'R-9985R-methotrexate', 'TCMDC-123832', 'TCMDC-125488', 'TCMDC-125858', 'Trexall']", 'yearOfFirstApproval': 1953, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis', 'approvedSymbol': 'DHFR', 'approvedName': 'dihydrofolate reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1841 | Q34 | What are the names of the genes that are targeted by the drug Ivacaftor in the treatment of respiratory system disease? | In the context of respiratory system disease, the drug Ivacaftor targets the gene CF transmembrane conductance regulator. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%respiratory system disease%" OR LOWER(efo_term) LIKE "%respiratory system disease%") AND (LOWER(drugName) LIKE "%ivacaftor%" OR LOWER(tradeNames_list) LIKE "%ivacaftor%" OR LOWER(syns_list) LIKE "%ivacaftor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103315', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103336', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103343', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103350', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103364', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103371', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103378', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103392', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103399', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103406', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103413', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103427', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103434', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103441', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103448', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103455', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103462', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103469', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103476', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103483', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103490', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103504', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103511', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103518', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103525', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103532', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103546', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103553', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103560', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103567', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103574', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103581', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103588', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103595', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103602', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103609', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103616', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103623', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103630', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103637', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103644', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103651', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103658', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103665', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103672', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103679', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103686', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103693', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103700', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103497', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103385', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103329', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103301', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103287', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103280', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103539', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103420', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103357', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103322', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103308', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}, {'UUID': 'DrugTargetsIndication121923_text_1103294', 'drugName': 'Ivacaftor', 'tradeNames_list': "['Kalydeco']", 'syns_list': "['Ivacaftor', 'VX-770']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Respiratory Tract Diseases', 'efo_term': 'respiratory system disease', 'approvedSymbol': 'CFTR', 'approvedName': 'CF transmembrane conductance regulator'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.716 | Q34 | What are the names of the genes that are targeted by the drug Vemurafenib in the treatment of cancer? | In the context of cancer, the drug Vemurafenib targets the gene B-Raf proto-oncogene, serine/threonine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%vemurafenib%" OR LOWER(tradeNames_list) LIKE "%vemurafenib%" OR LOWER(syns_list) LIKE "%vemurafenib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_752220', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752115', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752094', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752178', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752199', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752157', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752136', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752177', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752219', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752156', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752093', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752135', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752198', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752114', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752165', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752144', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752081', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752207', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752123', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752102', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752186', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Skin Neoplasms', 'efo_term': 'skin cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752099', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752120', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752162', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752183', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752141', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752204', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_752225', 'drugName': 'Vemurafenib', 'tradeNames_list': "['Zelboraf']", 'syns_list': "['PLX-4032', 'PLX4032', 'RG 7204', 'RG-7204', 'RO 5185426', 'RO-51-85426RO-5185426', 'Vemurafenib']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 0.5, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1809 | Q34 | What are the names of the genes that are targeted by the drug Givosiran Sodium in the treatment of Acute hepatic porphyria? | In the context of Acute hepatic porphyria, the drug Givosiran Sodium targets the gene 5'-aminolevulinate synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute hepatic porphyria%" OR LOWER(efo_term) LIKE "%acute hepatic porphyria%") AND (LOWER(drugName) LIKE "%givosiran sodium%" OR LOWER(tradeNames_list) LIKE "%givosiran sodium%" OR LOWER(syns_list) LIKE "%givosiran sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100370', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100376', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100378', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100380', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100384', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100374', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100366', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100362', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100360', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100382', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100372', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100368', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}, {'UUID': 'DrugTargetsIndication121923_text_1100364', 'drugName': 'Givosiran Sodium', 'tradeNames_list': "['Givlaari']", 'syns_list': "['Givosiran sodium']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Porphyrias, Hepatic', 'efo_term': 'Acute hepatic porphyria', 'approvedSymbol': 'ALAS1', 'approvedName': "5'-aminolevulinate synthase 1"}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.970 | Q34 | What are the names of the genes that are targeted by the drug Upadacitinib in the treatment of rheumatoid arthritis? | In the context of rheumatoid arthritis, the drug Upadacitinib targets the gene Janus kinase 1, Janus kinase 3, tyrosine kinase 2 and Janus kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%rheumatoid arthritis%" OR LOWER(efo_term) LIKE "%rheumatoid arthritis%") AND (LOWER(drugName) LIKE "%upadacitinib%" OR LOWER(tradeNames_list) LIKE "%upadacitinib%" OR LOWER(syns_list) LIKE "%upadacitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_846833', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846869', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846881', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846893', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846917', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846929', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846941', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846965', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846977', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846989', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847001', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847025', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847037', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847049', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847061', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847073', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847085', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847097', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847109', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847121', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847133', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847157', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847169', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847181', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847193', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847205', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847229', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847241', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847253', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847265', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847277', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847289', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847301', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847313', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847325', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847337', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847349', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847361', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847373', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847385', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847397', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847409', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847421', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847433', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847445', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847457', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847469', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847481', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847493', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847505', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847517', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847541', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847553', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847565', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847577', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847589', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847601', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847625', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847637', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847649', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847661', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847673', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847685', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847697', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847709', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847721', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847733', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847745', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847757', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847769', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847781', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847793', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847805', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847817', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847829', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847841', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847853', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847865', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847877', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847889', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847901', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847913', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847925', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847937', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847949', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847961', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK2', 'approvedName': 'Janus kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847529', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847145', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846953', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846857', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846809', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846785', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846773', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_847613', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'TYK2', 'approvedName': 'tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_847217', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK3', 'approvedName': 'Janus kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_847013', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846905', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846845', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846821', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_846797', 'drugName': 'Upadacitinib', 'tradeNames_list': "['Rinvoq']", 'syns_list': "['ABT-494', 'Upadacitinib', 'Upadacitinib anhydrousUpadacitinib hemihydrate', 'Upadacitinib hydrate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Rheumatoid', 'efo_term': 'rheumatoid arthritis', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1113 | Q34 | What are the names of the genes that are targeted by the drug Tucatinib in the treatment of breast cancer? | In the context of breast cancer, the drug Tucatinib targets the gene erb-b2 receptor tyrosine kinase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast cancer%" OR LOWER(efo_term) LIKE "%breast cancer%") AND (LOWER(drugName) LIKE "%tucatinib%" OR LOWER(tradeNames_list) LIKE "%tucatinib%" OR LOWER(syns_list) LIKE "%tucatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_924482', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924468', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924552', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924524', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924454', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924538', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924496', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924510', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924502', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924516', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924544', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924474', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924460', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924446', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924530', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_924488', 'drugName': 'Tucatinib', 'tradeNames_list': "['Tukysa']", 'syns_list': "['ARRY-380', 'Irbinitinib', 'ONT-380', 'Ont-380', 'Tucatinib']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Triple Negative Breast Neoplasms', 'efo_term': 'triple-negative breast cancer', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.11 | Q34 | What are the names of the genes that are targeted by the drug Risperidone in the treatment of schizoaffective disorder? | In the context of schizoaffective disorder, the drug Risperidone targets the gene 5-hydroxytryptamine receptor 2C, dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizoaffective disorder%" OR LOWER(efo_term) LIKE "%schizoaffective disorder%") AND (LOWER(drugName) LIKE "%risperidone%" OR LOWER(tradeNames_list) LIKE "%risperidone%" OR LOWER(syns_list) LIKE "%risperidone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_149656', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149755', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149788', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149821', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149887', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149920', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149953', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150019', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150052', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150085', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150118', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150184', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150217', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150250', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150283', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150316', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150349', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150382', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150415', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150448', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150481', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150547', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150580', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150613', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150646', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_150679', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150745', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150778', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150811', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150844', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150877', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150910', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150943', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150976', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151009', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151042', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151075', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151108', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151141', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151174', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151207', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_151240', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150514', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149986', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149722', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149590', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149524', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149491', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_150712', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_150151', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_149854', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149689', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149623', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}, {'UUID': 'DrugTargetsIndication121923_text_149557', 'drugName': 'Risperidone', 'tradeNames_list': "['Perseris kit', 'Risperdal', 'Risperdal Consta Long Acting', 'Risperdal MRisperdal M-Tab', 'Risperdal consta', 'Risperdal quicklet', 'Risperidone']", 'syns_list': "['LY-03004', 'LY03004', 'N05AX08', 'NSC-759895', 'Perseris', 'R 64 766R-64,766', 'R-64-766', 'R-64766', 'RCN-3028', 'RCN3028', 'Risperidone']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psychotic Disorders', 'efo_term': 'schizoaffective disorder', 'approvedSymbol': 'HTR2C', 'approvedName': '5-hydroxytryptamine receptor 2C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1680 | Q34 | What are the names of the genes that are targeted by the drug Canagliflozin in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Canagliflozin targets the gene solute carrier family 5 member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%canagliflozin%" OR LOWER(tradeNames_list) LIKE "%canagliflozin%" OR LOWER(syns_list) LIKE "%canagliflozin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1095947', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096064', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096136', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095929', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096163', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096172', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096074', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096019', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096209', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095921', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096236', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096028', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095965', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095956', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095975', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096218', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096155', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096056', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095912', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096137', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095939', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096092', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096100', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095902', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096217', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095948', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096128', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096038', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095911', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096191', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095957', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096145', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095938', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096190', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096037', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095903', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095966', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095974', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096047', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096055', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096020', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096164', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096173', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095930', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096065', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095983', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096073', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096029', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095984', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096082', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096083', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096091', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096046', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095993', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096200', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096101', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096001', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096227', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096002', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096118', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096119', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096226', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096127', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096182', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096235', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096208', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096199', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095992', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095920', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096181', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096110', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096011', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096109', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096010', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096146', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096154', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096123', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096132', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095925', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096015', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096141', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096150', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095961', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096159', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096168', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096033', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096177', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095916', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096024', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095934', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095970', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096042', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096186', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096195', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096051', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096060', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095979', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096069', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1095988', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}, {'UUID': 'DrugTargetsIndication121923_text_1096078', 'drugName': 'Canagliflozin', 'tradeNames_list': "['Invokana']", 'syns_list': "['Canagliflozin', 'Canagliflozin hemihydrate', 'Canagliflozin hydrateJNJ-24831754-ZAE', 'JNJ-28431754', 'JNJ-28431754-AAA', 'TA-7284']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'SLC5A2', 'approvedName': 'solute carrier family 5 member 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1938 | Q34 | What are the names of the genes that are targeted by the drug Belzutifan in the treatment of pancreatic neuroendocrine tumor? | In the context of pancreatic neuroendocrine tumor, the drug Belzutifan targets the gene endothelial PAS domain protein 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pancreatic neuroendocrine tumor%" OR LOWER(efo_term) LIKE "%pancreatic neuroendocrine tumor%") AND (LOWER(drugName) LIKE "%belzutifan%" OR LOWER(tradeNames_list) LIKE "%belzutifan%" OR LOWER(syns_list) LIKE "%belzutifan%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192113', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}, {'UUID': 'DrugTargetsIndication121923_text_1192121', 'drugName': 'Belzutifan', 'tradeNames_list': "['Welireg']", 'syns_list': "['Belzutifan', 'MK-6482', 'MK6482', 'Mk-6482', 'PT-2977', 'PT2977', 'Pt 2977Pt2977']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pancreatic neuroendocrine tumor', 'approvedSymbol': 'EPAS1', 'approvedName': 'endothelial PAS domain protein 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.284 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of Thrombocytopenia? | In the context of Thrombocytopenia, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombocytopenia%" OR LOWER(efo_term) LIKE "%thrombocytopenia%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227739', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228594', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228879', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229164', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229734', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230019', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230304', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230874', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231159', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231444', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231729', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232299', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230589', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228309', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227169', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226599', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226314', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232014', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229449', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228024', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227454', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226884', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombocytopenia', 'efo_term': 'Thrombocytopenia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1080 | Q34 | What are the names of the genes that are targeted by the drug Enzalutamide in the treatment of neoplasm? | In the context of neoplasm, the drug Enzalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%enzalutamide%" OR LOWER(tradeNames_list) LIKE "%enzalutamide%" OR LOWER(syns_list) LIKE "%enzalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921184', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921128', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921143', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921032', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921222', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921105', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921109', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921069', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921202', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921047', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921218', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921086', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921051', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921313', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921166', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921314', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921220', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921238', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921107', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921242', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921066', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921068', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921124', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921070', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921259', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921030', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921200', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921280', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921031', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921204', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921085', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921295', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921087', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921088', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921089', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921317', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921052', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921299', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921221', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921316', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921237', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921315', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921104', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921332', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921106', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921183', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921108', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921318', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921239', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921241', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921240', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921029', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921203', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921123', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921256', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921125', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921126', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921275', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921071', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921258', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921185', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921261', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921199', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921260', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921142', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921297', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921144', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921145', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921146', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921279', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921049', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921278', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921277', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921296', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921050', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921294', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921161', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921162', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921163', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921164', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921165', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921333', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921090', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921182', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921181', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921335', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate adenocarcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921334', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921298', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921276', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921257', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921219', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921033', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921067', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921127', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate carcinoma', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921201', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921147', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921223', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921028', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921048', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921180', 'drugName': 'Enzalutamide', 'tradeNames_list': "['Xtandi']", 'syns_list': "['Enzalutamide', 'MDV-3100', 'MDV3100', 'Mdv 3100']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.293 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of infection? | In the context of infection, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%infection%" OR LOWER(efo_term) LIKE "%infection%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_230313', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228603', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230883', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228318', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226323', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229458', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231168', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231453', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228888', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227178', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229173', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227463', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227748', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231738', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230028', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232023', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230598', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228033', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229743', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232308', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226608', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226893', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Infections', 'efo_term': 'infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226526', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227951', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229661', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229376', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230516', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229946', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227096', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230231', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226241', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227381', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228521', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230801', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231086', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228806', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231371', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231656', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226811', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227666', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229091', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231941', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232226', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228236', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Urinary Tract Infections', 'efo_term': 'urinary tract infection', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.759 | Q34 | What are the names of the genes that are targeted by the drug Oxycodone in the treatment of substance abuse? | In the context of substance abuse, the drug Oxycodone targets the gene opioid receptor mu 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%substance abuse%" OR LOWER(efo_term) LIKE "%substance abuse%") AND (LOWER(drugName) LIKE "%oxycodone%" OR LOWER(tradeNames_list) LIKE "%oxycodone%" OR LOWER(syns_list) LIKE "%oxycodone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_768125', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768224', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768257', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768290', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768356', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768389', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768422', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768488', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768521', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768554', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768587', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768653', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768686', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768719', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768752', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768785', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768818', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768851', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768884', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768917', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768950', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769016', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769049', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769082', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769115', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769148', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769214', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769247', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769280', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769313', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769346', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769379', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769412', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769445', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769478', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769511', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769544', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769577', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769610', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769643', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769676', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769709', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769742', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769775', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769808', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769841', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769874', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769907', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769940', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769973', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770006', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770072', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770105', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770138', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770171', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770204', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770237', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770303', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770336', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770369', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770402', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770435', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770468', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770501', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770534', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770567', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770600', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770633', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770666', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770699', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770732', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770765', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770798', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770831', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770864', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770897', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770930', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770963', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770996', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771029', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771062', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771095', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771128', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771161', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771194', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_771227', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770039', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768983', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768455', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768191', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768059', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_767993', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_767960', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_770270', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_769181', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768620', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768323', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768158', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768092', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}, {'UUID': 'DrugTargetsIndication121923_text_768026', 'drugName': 'Oxycodone', 'tradeNames_list': "['Oxycontin', 'Proladone', 'Xtampza er']", 'syns_list': "['(-)-14-hydroxydihydrocodeinone', '14-hydroxydihydrocodeinone', 'DihydroneIDS-NO-002', 'N02AA05', 'NSC-19043', 'Oxicone', 'Oxycodone', 'Oxycodone ciiOxymorphone 3-methyl ether', 'PF-00345439', 'PTI-821', 'Pavinal', 'Pti 821Remoxy', 'Xtampza']", 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Substance-Related Disorders', 'efo_term': 'substance abuse', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.631 | Q34 | What are the names of the genes that are targeted by the drug Sorafenib Tosylate in the treatment of thyroid cancer? | In the context of thyroid cancer, the drug Sorafenib Tosylate targets the gene kinase insert domain receptor, B-Raf proto-oncogene, serine/threonine kinase, fms related receptor tyrosine kinase 1, fms related receptor tyrosine kinase 3, KIT proto-oncogene, receptor tyrosine kinase, fms related receptor tyrosine kinase 4, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and ret proto-oncogene. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thyroid cancer%" OR LOWER(efo_term) LIKE "%thyroid cancer%") AND (LOWER(drugName) LIKE "%sorafenib tosylate%" OR LOWER(tradeNames_list) LIKE "%sorafenib tosylate%" OR LOWER(syns_list) LIKE "%sorafenib tosylate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_683542', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683725', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683786', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683847', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683969', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684030', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684091', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_684213', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684274', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684335', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684396', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_684518', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684579', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684640', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684701', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684762', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684823', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684884', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_684945', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685006', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_685067', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685189', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685250', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685311', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_685372', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685433', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685555', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685616', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_685677', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685738', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685799', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685860', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685921', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_685128', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta'}, {'UUID': 'DrugTargetsIndication121923_text_684152', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT3', 'approvedName': 'fms related receptor tyrosine kinase 3'}, {'UUID': 'DrugTargetsIndication121923_text_683664', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683420', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683298', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683237', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_685494', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_684457', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683908', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_683603', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_683481', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_683359', 'drugName': 'Sorafenib Tosylate', 'tradeNames_list': "['Nexavar']", 'syns_list': "['BAY 54-9085', 'BAY-54-9085', 'Sorafenib tosilate', 'Sorafenib tosylate']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.909 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of juvenile idiopathic arthritis? | In the context of juvenile idiopathic arthritis, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%juvenile idiopathic arthritis%" OR LOWER(efo_term) LIKE "%juvenile idiopathic arthritis%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838130', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838181', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838198', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838215', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838249', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838266', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838283', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838332', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838373', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838414', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838455', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838537', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838578', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838619', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838660', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838701', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838742', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838783', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838824', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838865', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838906', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838988', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839029', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839070', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839111', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839152', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839234', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839275', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839316', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839357', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839398', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839439', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839480', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839521', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839562', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839603', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839644', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839685', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838947', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838300', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838164', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838096', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838062', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838045', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839193', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838496', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838232', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838147', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838113', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838079', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Juvenile', 'efo_term': 'juvenile idiopathic arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.830 | Q34 | What are the names of the genes that are targeted by the drug Acetaminophen in the treatment of arthritis? | In the context of arthritis, the drug Acetaminophen targets the gene prostaglandin-endoperoxide synthase 2, prostaglandin-endoperoxide synthase 1, transient receptor potential cation channel subfamily V member 1 and fatty acid amide hydrolase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%arthritis%" OR LOWER(efo_term) LIKE "%arthritis%") AND (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_list) LIKE "%acetaminophen%" OR LOWER(syns_list) LIKE "%acetaminophen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_832727', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831467', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832832', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830207', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829787', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_832202', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_830942', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832412', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_832622', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831677', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830522', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831992', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828842', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831572', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829367', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830312', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829892', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829997', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829682', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831782', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831257', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831362', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830417', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830102', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831047', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832307', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_829577', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829052', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829472', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829262', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832097', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828947', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830837', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_832517', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_831887', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase'}, {'UUID': 'DrugTargetsIndication121923_text_828737', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829157', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830732', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830627', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831152', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis', 'efo_term': 'arthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831131', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831139', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829672', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830816', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829984', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828724', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829766', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829882', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829879', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828934', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830827', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829871', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828926', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829451', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830197', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829042', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831236', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829774', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829777', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830711', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829241', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830722', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828937', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831244', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830299', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829249', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_831142', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830614', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830606', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830302', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829564', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828716', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830921', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829252', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830932', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_831034', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_830501', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830404', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830396', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830617', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830407', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830929', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829556', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830509', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829462', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830719', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830291', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_830824', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829459', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830512', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_831026', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_829567', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829136', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_830194', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_829144', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829661', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829147', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis', 'efo_term': 'osteoarthritis', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829669', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Hip', 'efo_term': 'osteoarthritis, hip', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828821', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_829976', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'syns_list': "['Acetaminophen', 'Apap', 'Biocetamol', 'Doliprane', 'EfferalganN-acetyl-p-aminophenol', 'NSC-109028', 'NSC-3991', 'P-hydroxy-acetanilidParacetamol', 'Paracetamolum', 'Vermidon']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Osteoarthritis, Knee', 'efo_term': 'osteoarthritis, knee', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.131 | Q34 | What are the names of the genes that are targeted by the drug Brigatinib in the treatment of neoplasm? | In the context of neoplasm, the drug Brigatinib targets the gene epidermal growth factor receptor and ALK receptor tyrosine kinase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%brigatinib%" OR LOWER(tradeNames_list) LIKE "%brigatinib%" OR LOWER(syns_list) LIKE "%brigatinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_207119', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207128', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207131', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207134', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207140', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207143', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207146', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207152', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207155', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207158', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207161', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207167', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207170', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207173', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207149', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207125', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207113', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207107', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207104', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207164', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_207137', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207122', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207116', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}, {'UUID': 'DrugTargetsIndication121923_text_207110', 'drugName': 'Brigatinib', 'tradeNames_list': "['Alunbrig']", 'syns_list': "['AP-26113', 'AP26113', 'Ap-26113', 'Brigatinib']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1281 | Q34 | What are the names of the genes that are targeted by the drug Pralsetinib in the treatment of cancer? | In the context of cancer, the drug Pralsetinib targets the gene ret proto-oncogene, coiled-coil domain containing 6 and kinesin family member 5B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%pralsetinib%" OR LOWER(tradeNames_list) LIKE "%pralsetinib%" OR LOWER(syns_list) LIKE "%pralsetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_944311', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944323', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944327', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944331', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944339', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944343', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944347', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944355', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944359', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944363', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944367', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'KIF5B', 'approvedName': 'kinesin family member 5B'}, {'UUID': 'DrugTargetsIndication121923_text_944319', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944303', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944295', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944291', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944351', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'CCDC6', 'approvedName': 'coiled-coil domain containing 6'}, {'UUID': 'DrugTargetsIndication121923_text_944335', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944315', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944307', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_944299', 'drugName': 'Pralsetinib', 'tradeNames_list': "['Gavreto']", 'syns_list': "[':pralsetinib', 'BLU-123244', 'BLU-667', 'BLU123244', 'Blu-667', 'PralsetinibX-581238', 'X581238']", 'yearOfFirstApproval': 2020, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.325 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of hemorrhoid? | In the context of hemorrhoid, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhoid%" OR LOWER(efo_term) LIKE "%hemorrhoid%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227781', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228636', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228921', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229206', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229776', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230061', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230346', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230916', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231201', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231486', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231771', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232341', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230631', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228351', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227211', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226641', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226356', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232056', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229491', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228066', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227496', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226926', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hemorrhoids', 'efo_term': 'hemorrhoid', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1826 | Q34 | What are the names of the genes that are targeted by the drug Cyclosporine in the treatment of inflammation? | In the context of inflammation, the drug Cyclosporine targets the gene peptidylprolyl isomerase A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%inflammation%" OR LOWER(efo_term) LIKE "%inflammation%") AND (LOWER(drugName) LIKE "%cyclosporine%" OR LOWER(tradeNames_list) LIKE "%cyclosporine%" OR LOWER(syns_list) LIKE "%cyclosporine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1101279', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101660', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101787', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101914', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102168', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102295', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102422', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102676', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102803', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102930', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1103057', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101533', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101025', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100771', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100644', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102549', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1102041', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101406', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1101152', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}, {'UUID': 'DrugTargetsIndication121923_text_1100898', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'syns_list': "['27-400', 'ANTIBIOTIC S-7481F1', 'Atopica', 'Ciclosporin', 'Ciclosporin aCiclosporinum', 'Cyclosporin', 'Cyclosporin a', 'CyclosporineCyclosporine a', 'Cyclosporine microemulsion', 'Cyclosporine, modifiedEquoral', 'Mitogard', 'NSC-290193', 'Neoplanta', 'Neurostat', 'OL-27-400Ramihyphin a', 'SANG-35', 'SDZ-OXL-400', 'Zinograf me']", 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Inflammation', 'efo_term': 'inflammation', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.815 | Q34 | What are the names of the genes that are targeted by the drug Indomethacin in the treatment of pain? | In the context of pain, the drug Indomethacin targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%indomethacin%" OR LOWER(tradeNames_list) LIKE "%indomethacin%" OR LOWER(syns_list) LIKE "%indomethacin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828372', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828474', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828508', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828542', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828440', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828304', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828236', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828202', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828576', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828406', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_828338', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_828270', 'drugName': 'Indomethacin', 'tradeNames_list': "['Artracin', 'Artracin sr', 'Berlind 75 ret', 'Flexin-25 continusFlexin-50 continus', 'Flexin-75 continus', 'Imbrilon', 'Indo-lemmonIndo-paed', 'Indocid ret', 'Indocid-r', 'Indocin', 'Indocin sr', 'IndodermIndoflex', 'Indolar', 'Indolar sr', 'Indomax-25', 'Indomax-75 srIndomethacin', 'Indomod', 'Indoptol', 'Indotard mr 75', 'LedmecinMaximet sr', 'Mobilan', 'Pardelprin mr', 'Rheumacin la', 'RimacidSlo-indo', 'Tivorbex']", 'syns_list': "['Aconip', 'Durametacin', 'Indometacin', 'Indometacin farnesilIndometacinum', 'Indomethacin', 'NSC-757061', 'NSC-77541', 'Reumacide']", 'yearOfFirstApproval': 1965, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acute Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.928 | Q34 | What are the names of the genes that are targeted by the drug Ibuprofen in the treatment of Myalgia? | In the context of Myalgia, the drug Ibuprofen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%myalgia%" OR LOWER(efo_term) LIKE "%myalgia%") AND (LOWER(drugName) LIKE "%ibuprofen%" OR LOWER(tradeNames_list) LIKE "%ibuprofen%" OR LOWER(syns_list) LIKE "%ibuprofen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_840158', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840395', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840474', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840553', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840711', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840790', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840869', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841027', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841106', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841185', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841264', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841422', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841501', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841580', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841659', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_841738', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840948', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840316', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840000', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839842', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839763', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_841343', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_840632', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840237', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_840079', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839921', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'syns_list': "['Burana', 'IB-100', 'IP-82', 'Ibuprofen', 'Ibuprofenum', 'M01AE01NSC-256857', 'RD 13621', 'U-18,573', 'U-18573']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Myalgia', 'efo_term': 'Myalgia', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1848 | Q34 | What are the names of the genes that are targeted by the drug Simvastatin in the treatment of coronary artery disease? | In the context of coronary artery disease, the drug Simvastatin targets the gene 3-hydroxy-3-methylglutaryl-CoA reductase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%coronary artery disease%" OR LOWER(efo_term) LIKE "%coronary artery disease%") AND (LOWER(drugName) LIKE "%simvastatin%" OR LOWER(tradeNames_list) LIKE "%simvastatin%" OR LOWER(syns_list) LIKE "%simvastatin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1104004', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104108', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103900', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103796', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103795', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104107', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1104003', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}, {'UUID': 'DrugTargetsIndication121923_text_1103899', 'drugName': 'Simvastatin', 'tradeNames_list': "['Flolipid', 'Lacersa', 'Ranzolont', 'Simvador', 'Simvastatin', 'ZocorZocor heart-pro']", 'syns_list': "['C10AA01', 'MK-0733', 'MK-733', 'NSC-758706', 'SimvastatinSimvastatin hydroxy acid', 'Synvinolin']", 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Coronary Artery Disease', 'efo_term': 'coronary artery disease', 'approvedSymbol': 'HMGCR', 'approvedName': '3-hydroxy-3-methylglutaryl-CoA reductase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1295 | Q34 | What are the names of the genes that are targeted by the drug Glucagon in the treatment of diabetes mellitus? | In the context of diabetes mellitus, the drug Glucagon targets the gene glucagon receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes mellitus%" OR LOWER(efo_term) LIKE "%diabetes mellitus%") AND (LOWER(drugName) LIKE "%glucagon%" OR LOWER(tradeNames_list) LIKE "%glucagon%" OR LOWER(syns_list) LIKE "%glucagon%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_968349', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968351', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968325', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968333', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968309', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968341', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968301', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968353', 'drugName': 'Dasiglucagon Hydrochloride', 'tradeNames_list': "['Zegalogue', 'Zegalogue (autoinjector)']", 'syns_list': "['Dasiglucagon hydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968293', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968317', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968339', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968323', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968299', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968315', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968347', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968291', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968307', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968331', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Diabetes Mellitus, Type 1', 'efo_term': 'type 1 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968287', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968295', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968327', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968335', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968311', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968343', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968303', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}, {'UUID': 'DrugTargetsIndication121923_text_968319', 'drugName': 'Glucagon', 'tradeNames_list': "['Baqsimi', 'Glucagen Hypokit', 'Glucagon', 'Glucagon Emergency KitGvoke hypopen', 'Gvoke pfs']", 'syns_list': "['Glucagon', 'Glucagon recombinant']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Diabetes Mellitus, Type 2', 'efo_term': 'type 2 diabetes mellitus', 'approvedSymbol': 'GCGR', 'approvedName': 'glucagon receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1291 | Q34 | What are the names of the genes that are targeted by the drug Alectinib in the treatment of cancer? | In the context of cancer, the drug Alectinib targets the gene ret proto-oncogene, ALK receptor tyrosine kinase and EMAP like 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%alectinib%" OR LOWER(tradeNames_list) LIKE "%alectinib%" OR LOWER(syns_list) LIKE "%alectinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_945632', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945613', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945689', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945746', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945803', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945784', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945822', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945594', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945708', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945765', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945841', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945860', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945651', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945879', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945727', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945670', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945653', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945729', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945748', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945672', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945767', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945786', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945862', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945596', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945691', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_945805', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945824', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945615', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945577', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945634', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene'}, {'UUID': 'DrugTargetsIndication121923_text_945843', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'EML4', 'approvedName': 'EMAP like 4'}, {'UUID': 'DrugTargetsIndication121923_text_945710', 'drugName': 'Alectinib', 'tradeNames_list': "['Alecensa']", 'syns_list': "['AF-802', 'AF802', 'Alectinib', 'CH-5424802', 'CH5424802', 'RO-5424802RO5424802']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Glioma', 'efo_term': 'central nervous system cancer', 'approvedSymbol': 'ALK', 'approvedName': 'ALK receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.700 | Q34 | What are the names of the genes that are targeted by the drug Apixaban in the treatment of thrombotic disease? | In the context of thrombotic disease, the drug Apixaban targets the gene coagulation factor X. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%thrombotic disease%" OR LOWER(efo_term) LIKE "%thrombotic disease%") AND (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_list) LIKE "%apixaban%" OR LOWER(syns_list) LIKE "%apixaban%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_710510', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710597', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710626', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710655', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710713', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710742', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710771', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710568', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710452', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710394', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710365', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710684', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710539', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710481', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}, {'UUID': 'DrugTargetsIndication121923_text_710423', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'syns_list': "['Apixaban', 'BMS-562247', 'BMS-562247-01']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.217 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of sarcoidosis? | In the context of sarcoidosis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%sarcoidosis%" OR LOWER(efo_term) LIKE "%sarcoidosis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218099', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217891', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218723', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219347', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219971', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219763', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220179', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217683', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218931', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219555', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220387', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220595', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218307', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220803', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219139', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218515', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Sarcoidosis', 'efo_term': 'sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218387', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219219', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219427', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218595', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219635', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219843', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220675', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217763', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218803', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220051', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220259', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217971', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217555', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218179', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220467', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219011', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Sarcoidosis, Pulmonary', 'efo_term': 'pulmonary sarcoidosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1261 | Q34 | What are the names of the genes that are targeted by the drug Drospirenone in the treatment of acne? | In the context of acne, the drug Drospirenone targets the gene progesterone receptor and nuclear receptor subfamily 3 group C member 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acne%" OR LOWER(efo_term) LIKE "%acne%") AND (LOWER(drugName) LIKE "%drospirenone%" OR LOWER(tradeNames_list) LIKE "%drospirenone%" OR LOWER(syns_list) LIKE "%drospirenone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_939886', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939910', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939918', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939926', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939942', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939950', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939958', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939974', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939982', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939990', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939998', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_940014', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939966', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939902', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939870', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939854', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939846', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_940006', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939934', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'NR3C2', 'approvedName': 'nuclear receptor subfamily 3 group C member 2'}, {'UUID': 'DrugTargetsIndication121923_text_939894', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939878', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}, {'UUID': 'DrugTargetsIndication121923_text_939862', 'drugName': 'Drospirenone', 'tradeNames_list': "['Angeliq', 'Slynd']", 'syns_list': "['Drospirenone', 'NSC-760103', 'ZK 30595', 'ZK-30595']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Acne Vulgaris', 'efo_term': 'acne', 'approvedSymbol': 'PGR', 'approvedName': 'progesterone receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.160 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of Chorioretinitis? | In the context of Chorioretinitis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%chorioretinitis%" OR LOWER(efo_term) LIKE "%chorioretinitis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218666', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219290', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219498', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219706', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220122', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220330', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220538', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220746', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219082', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218250', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217834', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217626', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219914', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218874', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218458', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218042', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chorioretinitis', 'efo_term': 'Chorioretinitis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1047 | Q34 | What are the names of the genes that are targeted by the drug Levetiracetam in the treatment of epilepsy with generalized tonic-clonic seizures? | In the context of epilepsy with generalized tonic-clonic seizures, the drug Levetiracetam targets the gene calcium voltage-gated channel subunit alpha1 B and synaptic vesicle glycoprotein 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%epilepsy with generalized tonic-clonic seizures%" OR LOWER(efo_term) LIKE "%epilepsy with generalized tonic-clonic seizures%") AND (LOWER(drugName) LIKE "%levetiracetam%" OR LOWER(tradeNames_list) LIKE "%levetiracetam%" OR LOWER(syns_list) LIKE "%levetiracetam%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_914953', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915085', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915129', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915173', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915261', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915305', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915349', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915437', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915481', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915525', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915569', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915657', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915701', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915745', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915789', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915833', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915877', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915921', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915965', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916009', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916053', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916141', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916185', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916229', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916273', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916317', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916405', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916449', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_916493', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916537', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916581', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916625', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916669', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916713', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916757', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916801', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916845', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916889', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916933', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916977', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917021', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917065', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917109', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917153', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917197', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917241', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917285', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917329', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917373', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917417', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917461', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917549', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917593', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917637', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917681', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917725', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917769', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917857', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917901', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917945', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917989', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918033', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918077', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918121', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918165', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_918209', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_917505', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916097', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915393', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915041', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914865', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914777', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914733', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_917813', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'SV2A', 'approvedName': 'synaptic vesicle glycoprotein 2A'}, {'UUID': 'DrugTargetsIndication121923_text_916361', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915613', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_915217', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914997', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914909', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}, {'UUID': 'DrugTargetsIndication121923_text_914821', 'drugName': 'Levetiracetam', 'tradeNames_list': "['Desitrend', 'Elepsia xr', 'Keppra', 'Keppra xr', 'LevetiracetamLevetiracetam in sodium chloride', 'Matever', 'Spritam']", 'syns_list': "['AGB-101', 'Elepsia', 'Levetiracetam', 'Levetiracetam accordLevetiracetam actavis', 'Levetiracetam hospira', 'Levetiracetam sunLevetiracetam teva', 'Levetiracetame', 'N03AX14', 'NSC-760119', 'UCB 22059UCB L059', 'UCB-22059', 'UCB-L059']", 'yearOfFirstApproval': 1999, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Epilepsy, Tonic-Clonic', 'efo_term': 'epilepsy with generalized tonic-clonic seizures', 'approvedSymbol': 'CACNA1B', 'approvedName': 'calcium voltage-gated channel subunit alpha1 B'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1816 | Q34 | What are the names of the genes that are targeted by the drug Montelukast in the treatment of allergic rhinitis? | In the context of allergic rhinitis, the drug Montelukast targets the gene cysteinyl leukotriene receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%allergic rhinitis%" OR LOWER(efo_term) LIKE "%allergic rhinitis%") AND (LOWER(drugName) LIKE "%montelukast%" OR LOWER(tradeNames_list) LIKE "%montelukast%" OR LOWER(syns_list) LIKE "%montelukast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100425', 'drugName': 'Montelukast', 'tradeNames_list': "['Singulair']", 'syns_list': "['Brondilat', 'MK-476', 'Montelukast']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100393', 'drugName': 'Montelukast Sodium', 'tradeNames_list': "['Montelukast sodium', 'Singulair']", 'syns_list': "['MK-476', 'Montelukast (as sodium)', 'Montelukast monosodium saltMontelukast sodium', 'NSC-759107']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100392', 'drugName': 'Montelukast Sodium', 'tradeNames_list': "['Montelukast sodium', 'Singulair']", 'syns_list': "['MK-476', 'Montelukast (as sodium)', 'Montelukast monosodium saltMontelukast sodium', 'NSC-759107']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100423', 'drugName': 'Montelukast', 'tradeNames_list': "['Singulair']", 'syns_list': "['Brondilat', 'MK-476', 'Montelukast']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100424', 'drugName': 'Montelukast', 'tradeNames_list': "['Singulair']", 'syns_list': "['Brondilat', 'MK-476', 'Montelukast']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100394', 'drugName': 'Montelukast Sodium', 'tradeNames_list': "['Montelukast sodium', 'Singulair']", 'syns_list': "['MK-476', 'Montelukast (as sodium)', 'Montelukast monosodium saltMontelukast sodium', 'NSC-759107']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic', 'efo_term': 'allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.639 | Q34 | What are the names of the genes that are targeted by the drug Axitinib in the treatment of renal cell carcinoma? | In the context of renal cell carcinoma, the drug Axitinib targets the gene kinase insert domain receptor, fms related receptor tyrosine kinase 1 and fms related receptor tyrosine kinase 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%renal cell carcinoma%" OR LOWER(efo_term) LIKE "%renal cell carcinoma%") AND (LOWER(drugName) LIKE "%axitinib%" OR LOWER(tradeNames_list) LIKE "%axitinib%" OR LOWER(syns_list) LIKE "%axitinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_689241', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689324', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689325', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689366', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689408', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689409', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689450', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689492', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689493', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689534', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689535', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689577', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689618', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689619', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689660', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689661', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689702', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689703', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689744', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689745', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689786', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689828', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689829', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689870', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689871', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689912', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689954', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689955', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689996', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689997', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690038', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690039', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690080', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690081', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690122', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_690123', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689787', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689451', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689283', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689199', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689157', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689156', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689913', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_689576', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_689367', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689282', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689240', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}, {'UUID': 'DrugTargetsIndication121923_text_689198', 'drugName': 'Axitinib', 'tradeNames_list': "['Inlyta']", 'syns_list': "['AG-013736', 'AG-13736', 'Axitinib', 'NSC-757441']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Carcinoma, Renal Cell', 'efo_term': 'papillary renal cell carcinoma', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.520 | Q34 | What are the names of the genes that are targeted by the drug Memantine Hydrochloride in the treatment of Alzheimer disease? | In the context of Alzheimer disease, the drug Memantine Hydrochloride targets the gene glutamate ionotropic receptor NMDA type subunit 1, glutamate ionotropic receptor NMDA type subunit 2A, glutamate ionotropic receptor NMDA type subunit 2B, glutamate ionotropic receptor NMDA type subunit 2D, glutamate ionotropic receptor NMDA type subunit 3B, glutamate ionotropic receptor NMDA type subunit 2C and glutamate ionotropic receptor NMDA type subunit 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%alzheimer disease%" OR LOWER(efo_term) LIKE "%alzheimer disease%") AND (LOWER(drugName) LIKE "%memantine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%memantine hydrochloride%" OR LOWER(syns_list) LIKE "%memantine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_455064', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455106', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455120', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455134', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455162', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455176', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455190', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455218', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455232', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455246', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455260', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455288', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455302', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455316', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455330', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455344', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455358', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455372', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455386', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455400', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455414', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455442', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455456', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455470', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455484', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455498', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455526', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455540', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455554', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455568', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455582', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455596', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455610', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455624', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455638', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455652', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2C', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2C'}, {'UUID': 'DrugTargetsIndication121923_text_455666', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455680', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455694', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455708', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455722', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455736', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455750', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455764', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3A'}, {'UUID': 'DrugTargetsIndication121923_text_455428', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2D', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2D'}, {'UUID': 'DrugTargetsIndication121923_text_455204', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455092', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455036', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455008', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_454994', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455512', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN3B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 3B'}, {'UUID': 'DrugTargetsIndication121923_text_455274', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2B', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2B'}, {'UUID': 'DrugTargetsIndication121923_text_455148', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN2A', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 2A'}, {'UUID': 'DrugTargetsIndication121923_text_455078', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455050', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_455022', 'drugName': 'Memantine Hydrochloride', 'tradeNames_list': "['Akatinol', 'Ebixa', 'Marixino', 'Memantine', 'Memantine hydrochlorideNamenda', 'Namenda xr', 'Nemdatine', 'Valios']", 'syns_list': "['Acrescent', 'Auxura', 'Balaxur', 'FP-01', 'Memantine accord', 'Memantine hclMemantine hydrochloride', 'Memantine lek', 'Memantine merzMemantine mylan', 'Memantine ratiopharm', 'Memary', 'NSC-102290SUN-Y7017']", 'yearOfFirstApproval': 2003, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Alzheimer Disease', 'efo_term': 'Alzheimer disease', 'approvedSymbol': 'GRIN1', 'approvedName': 'glutamate ionotropic receptor NMDA type subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1413 | Q34 | What are the names of the genes that are targeted by the drug Doxycycline in the treatment of Vibrio infectious disease? | In the context of Vibrio infectious disease, the drug Doxycycline targets the gene matrix metallopeptidase 7, matrix metallopeptidase 1, matrix metallopeptidase 13 and matrix metallopeptidase 8. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%vibrio infectious disease%" OR LOWER(efo_term) LIKE "%vibrio infectious disease%") AND (LOWER(drugName) LIKE "%doxycycline%" OR LOWER(tradeNames_list) LIKE "%doxycycline%" OR LOWER(syns_list) LIKE "%doxycycline%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1038227', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038452', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038527', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038602', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038752', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038827', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038902', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039052', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039127', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039202', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039277', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039427', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1039502', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039577', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039652', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039727', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039802', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039877', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1039952', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040027', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040102', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040252', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1040327', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040402', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040477', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040552', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040702', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040777', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040852', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040927', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041002', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1041077', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1040177', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP13', 'approvedName': 'matrix metallopeptidase 13'}, {'UUID': 'DrugTargetsIndication121923_text_1038977', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038377', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038077', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037927', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1037852', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1040627', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP8', 'approvedName': 'matrix metallopeptidase 8'}, {'UUID': 'DrugTargetsIndication121923_text_1039352', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038677', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP1', 'approvedName': 'matrix metallopeptidase 1'}, {'UUID': 'DrugTargetsIndication121923_text_1038302', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038152', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}, {'UUID': 'DrugTargetsIndication121923_text_1038002', 'drugName': 'Doxycycline', 'tradeNames_list': "['Doxychel', 'Doxycycline', 'Monodox', 'Oracea', 'Vibramycin']", 'syns_list': "['Doxirobe', 'Doxycycline', 'Doxycycline monohydrate', 'Doxylin', 'GS-3065Supracyclin', 'Xyrosa']", 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholera', 'efo_term': 'Vibrio infectious disease', 'approvedSymbol': 'MMP7', 'approvedName': 'matrix metallopeptidase 7'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.602 | Q34 | What are the names of the genes that are targeted by the drug Lamotrigine in the treatment of depressive disorder? | In the context of depressive disorder, the drug Lamotrigine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%depressive disorder%" OR LOWER(efo_term) LIKE "%depressive disorder%") AND (LOWER(drugName) LIKE "%lamotrigine%" OR LOWER(tradeNames_list) LIKE "%lamotrigine%" OR LOWER(syns_list) LIKE "%lamotrigine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_653063', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653121', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653125', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653152', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653183', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653187', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653214', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653245', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653249', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653276', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653280', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653311', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653338', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653342', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653369', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653373', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653400', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653404', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653431', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653435', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653462', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653493', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653497', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653524', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653528', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653555', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653586', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653590', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653617', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653621', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653648', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653652', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653679', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653683', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653710', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653714', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653741', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653745', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653772', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653776', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653803', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653807', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653834', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653838', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653865', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653869', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653896', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653900', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653927', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653931', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653958', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653989', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653993', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654020', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654024', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654051', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654055', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654086', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_654113', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654117', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654144', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654148', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654175', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654179', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654206', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654210', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654237', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654241', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654268', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654272', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654299', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654303', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654330', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654334', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654361', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654365', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654392', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654396', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654423', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654427', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654454', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654458', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_654485', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654489', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654516', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_654520', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_653962', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653466', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653218', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653094', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653032', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653001', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652997', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_654082', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_653559', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_653307', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653156', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'depressive disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653090', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653059', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_653028', 'drugName': 'Lamotrigine', 'tradeNames_list': "['Lamictal', 'Lamictal cd', 'Lamictal odt', 'Lamictal xr', 'Lamotrigine']", 'syns_list': "['BW 430C', 'BW-430C', 'Lamotrigine', 'NSC-759171']", 'yearOfFirstApproval': 1994, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Depressive Disorder', 'efo_term': 'unipolar depression', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.197 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of pulmonary tuberculosis? | In the context of pulmonary tuberculosis, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary tuberculosis%" OR LOWER(efo_term) LIKE "%pulmonary tuberculosis%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218703', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219327', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219535', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219743', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220159', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220367', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220575', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220783', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219119', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218287', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217871', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217663', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219951', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218911', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218495', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218079', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1629 | Q34 | What are the names of the genes that are targeted by the drug Dabigatran in the treatment of hemorrhage? | Dabigatran has not been approved by the FDA as a treatment for hemorrhage, but it is currently undergoing evaluation in clinical trials for this purpose. However, the proposed gene target name is coagulation factor II, thrombin. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hemorrhage%" OR LOWER(efo_term) LIKE "%hemorrhage%") AND (LOWER(drugName) LIKE "%dabigatran%" OR LOWER(tradeNames_list) LIKE "%dabigatran%" OR LOWER(syns_list) LIKE "%dabigatran%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1093462', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093495', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093506', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093517', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093539', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093550', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093561', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093583', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093594', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093605', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093616', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093638', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093649', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093660', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093671', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093682', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093693', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093704', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093715', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093726', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093737', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093759', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093770', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093781', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093792', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093803', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093825', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093836', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093847', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093858', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093869', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093880', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093891', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093902', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093913', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093924', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093935', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093946', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093957', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093968', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093979', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093990', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094001', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094012', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1094023', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093748', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093572', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093484', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093440', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093418', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093407', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093814', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093627', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093528', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093473', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093451', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}, {'UUID': 'DrugTargetsIndication121923_text_1093429', 'drugName': 'Dabigatran', 'tradeNames_list': "['Pradaxa']", 'syns_list': "['BIBR 953 ZW', 'BIBR-953', 'BIBR-953-ZW', 'DabigatranPradaxa (dabigatran)']", 'yearOfFirstApproval': -1, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Hemorrhage', 'efo_term': 'hemorrhage', 'approvedSymbol': 'F2', 'approvedName': 'coagulation factor II, thrombin'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.838 | Q34 | What are the names of the genes that are targeted by the drug Celecoxib in the treatment of Peptic ulcer? | In the context of Peptic ulcer, the drug Celecoxib targets the gene prostaglandin-endoperoxide synthase 2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer%" OR LOWER(efo_term) LIKE "%peptic ulcer%") AND (LOWER(drugName) LIKE "%celecoxib%" OR LOWER(tradeNames_list) LIKE "%celecoxib%" OR LOWER(syns_list) LIKE "%celecoxib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_833171', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833378', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833393', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833489', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833282', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833060', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832949', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_832934', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833504', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833267', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833156', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_833045', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'syns_list': "['Celecoxib', 'DFN-15', 'DFN15', 'NSC-719627', 'NSC-758624', 'SC-58635']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.413 | Q34 | What are the names of the genes that are targeted by the drug Hydrocortisone Butyrate in the treatment of skin disease? | In the context of skin disease, the drug Hydrocortisone Butyrate targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%skin disease%" OR LOWER(efo_term) LIKE "%skin disease%") AND (LOWER(drugName) LIKE "%hydrocortisone butyrate%" OR LOWER(tradeNames_list) LIKE "%hydrocortisone butyrate%" OR LOWER(syns_list) LIKE "%hydrocortisone butyrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243802', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'syns_list': "['Cortisol 17-butyrate', 'Hydrocortisone 17-butyrateHydrocortisone butyrate', 'Hydrocortisone-17-butyrate', 'NSC-758433']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_243806', 'drugName': 'Hydrocortisone Butyrate', 'tradeNames_list': "['Hydrocortisone butyrate', 'Locoid', 'Locoid c', 'Locoid creloLocoid lipocream']", 'syns_list': "['Cortisol 17-butyrate', 'Hydrocortisone 17-butyrateHydrocortisone butyrate', 'Hydrocortisone-17-butyrate', 'NSC-758433']", 'yearOfFirstApproval': 1982, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Skin Diseases', 'efo_term': 'skin disease', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.98 | Q34 | What are the names of the genes that are targeted by the drug Granisetron in the treatment of Nausea? | In the context of Nausea, the drug Granisetron targets the gene 5-hydroxytryptamine receptor 3A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nausea%" OR LOWER(efo_term) LIKE "%nausea%") AND (LOWER(drugName) LIKE "%granisetron%" OR LOWER(tradeNames_list) LIKE "%granisetron%" OR LOWER(syns_list) LIKE "%granisetron%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205762', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205767', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205768', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205776', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205780', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205781', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205782', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205791', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205794', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205795', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205796', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205805', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205808', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205809', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205810', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205818', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205819', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205822', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205823', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205824', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205790', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205766', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205753', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205749', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205748', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205804', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205777', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205763', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nausea', 'efo_term': 'Nausea', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205754', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'Chemotherapy-induced nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}, {'UUID': 'DrugTargetsIndication121923_text_205752', 'drugName': 'Granisetron', 'tradeNames_list': "['Kytril', 'Sancuso', 'Sustol']", 'syns_list': "['APF-530', 'APF530', 'BRL 43694', 'BRL-43694', 'Granisetron', 'LY-278584']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Postoperative Nausea and Vomiting', 'efo_term': 'post operative nausea and vomiting', 'approvedSymbol': 'HTR3A', 'approvedName': '5-hydroxytryptamine receptor 3A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1815 | Q34 | What are the names of the genes that are targeted by the drug Montelukast in the treatment of seasonal allergic rhinitis? | In the context of seasonal allergic rhinitis, the drug Montelukast targets the gene cysteinyl leukotriene receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seasonal allergic rhinitis%" OR LOWER(efo_term) LIKE "%seasonal allergic rhinitis%") AND (LOWER(drugName) LIKE "%montelukast%" OR LOWER(tradeNames_list) LIKE "%montelukast%" OR LOWER(syns_list) LIKE "%montelukast%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100392', 'drugName': 'Montelukast Sodium', 'tradeNames_list': "['Montelukast sodium', 'Singulair']", 'syns_list': "['MK-476', 'Montelukast (as sodium)', 'Montelukast monosodium saltMontelukast sodium', 'NSC-759107']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100423', 'drugName': 'Montelukast', 'tradeNames_list': "['Singulair']", 'syns_list': "['Brondilat', 'MK-476', 'Montelukast']", 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Rhinitis, Allergic, Seasonal', 'efo_term': 'seasonal allergic rhinitis', 'approvedSymbol': 'CYSLTR1', 'approvedName': 'cysteinyl leukotriene receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.912 | Q34 | What are the names of the genes that are targeted by the drug Naproxen in the treatment of gout? | In the context of gout, the drug Naproxen targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gout%" OR LOWER(efo_term) LIKE "%gout%") AND (LOWER(drugName) LIKE "%naproxen%" OR LOWER(tradeNames_list) LIKE "%naproxen%" OR LOWER(syns_list) LIKE "%naproxen%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_838134', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838185', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838202', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838219', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838253', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838270', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838287', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838336', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838337', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838377', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838378', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838419', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838459', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838460', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838500', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838501', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838541', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838542', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838582', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838583', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838623', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838664', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838665', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838705', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838706', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838746', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838787', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838788', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838828', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838829', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838869', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838870', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838910', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838911', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838951', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838952', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838992', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838993', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839033', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839034', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839074', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839075', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839115', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839116', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839156', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839157', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839197', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839198', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839238', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839239', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839279', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839320', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839321', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839361', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839362', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839402', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839403', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839444', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839484', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839485', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839525', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839526', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839566', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839567', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839607', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839608', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839648', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839649', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839689', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839690', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_839280', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838624', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838304', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838168', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838100', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838066', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838049', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_839443', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838747', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Arthritis, Gouty', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838418', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'syns_list': "['Aleve', 'Anaprox', 'NSC-750183', 'NSC-757239', 'Naprelan', 'NaproxenPN400 COMPONENT NAPROXEN', 'RS-3540']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838236', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_838151', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838117', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_838083', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'syns_list': "['BAY-117031', 'BAY117031', 'BAYH6689', 'Naproxen sodiumNaproxen sodium anhydrous', 'Naproxen sodium salt', 'RS-3650']", 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gout', 'efo_term': 'gout', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.158 | Q34 | What are the names of the genes that are targeted by the drug Prednisone in the treatment of Aplastic anemia? | In the context of Aplastic anemia, the drug Prednisone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%aplastic anemia%" OR LOWER(efo_term) LIKE "%aplastic anemia%") AND (LOWER(drugName) LIKE "%prednisone%" OR LOWER(tradeNames_list) LIKE "%prednisone%" OR LOWER(syns_list) LIKE "%prednisone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_218664', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219288', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219496', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219704', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220120', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220328', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220536', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_220744', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219080', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218248', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217832', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_217624', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_219912', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218872', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218456', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_218040', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'syns_list': "['3en3hg4wsw', 'Decortin', 'Dehydrocortisone', 'Metacortandracin', 'NSC-10023Prednisone', 'Prednisone anhydrous', 'Prednisone tablets', 'Supercortil']", 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Aplastic', 'efo_term': 'Aplastic anemia', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.422 | Q34 | What are the names of the genes that are targeted by the drug Fenofibrate in the treatment of hypothyroidism? | In the context of hypothyroidism, the drug Fenofibrate targets the gene peroxisome proliferator activated receptor alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypothyroidism%" OR LOWER(efo_term) LIKE "%hypothyroidism%") AND (LOWER(drugName) LIKE "%fenofibrate%" OR LOWER(tradeNames_list) LIKE "%fenofibrate%" OR LOWER(syns_list) LIKE "%fenofibrate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_244086', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244173', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244202', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244231', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244289', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244318', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244347', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244405', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244434', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244376', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244144', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243970', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243941', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244028', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244260', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244115', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_244057', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}, {'UUID': 'DrugTargetsIndication121923_text_243999', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'syns_list': "['Fenofibrate', 'Fenofibrate delayed release', 'Fenofibrate micronizedNSC-281319']", 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypothyroidism', 'efo_term': 'hypothyroidism', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1786 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of prostate cancer? | In the context of prostate cancer, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099718', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099818', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099828', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099873', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099928', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099938', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099983', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100038', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100048', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100093', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100103', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100158', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100203', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100213', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099993', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099773', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099663', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099608', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099598', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100148', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099883', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099763', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099708', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099653', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.